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Abstract 
Large-scale neuroimaging in Alzheimer’s disease and normal aging 
Xinyang Feng 
Large-scale neuroimaging data is becoming increasingly available, providing a rich data source 
with which to study neurological conditions. In this thesis, I demonstrate the utility of large-scale 
neuroimaging as it applies to Alzheimer’s disease (AD) and normal aging, using univariate 
parametric mapping, regional analysis, and advanced machine learning. Specifically, this thesis 
covers: 1) validation and extension of prior studies using large-scale datasets; 2) AD diagnosis and 
normal aging evaluation empowered by large-scale datasets and advanced deep learning 
algorithms; 3) enhancement of cerebral blood volume (CBV) fMRI utility with retrospective CBV-
fMRI technique. 
 First, I demonstrated the utility of large-scale datasets for validating and extending prior 
studies using univariate analytics. I presented a study localizing AD-vulnerable regions more 
reliably and with better anatomical resolution using data from more than 350 subjects. Following 
a similar approach, I investigated the structural characteristics of healthy APOE ε4 homozygous 
subjects screened from a large-scale community-based study. To study the neuroimaging 
signatures of normal aging, we performed a large-scale joint CBV-fMRI and structural MRI study 
covering age 20-70s, and a structural MRI study of normal aging covering the full age-span, with 
the elder group screened from a large-scale clinic-based study ensuring no evidence of AD using 
both longitudinal follow-up and cerebrospinal fluid (CSF) biomarkers evidences. 
 Second, I performed deep learning neuroimaging studies for AD diagnosis and normal 
aging evaluation, and investigated the regionality associated with each task. I developed an AD 
diagnosis method using a 3D convolutional neural network model trained and evaluated on ~4,600 
structural MRI scans and further investigated a series of novel regionality analyses. I further 
extensively studied the utility of the structural MRI summary measure derived from the deep 
learning model in prodromal AD detection. This study constitutes a general analytic framework, 
which was followed to evaluate normal aging by performing deep learning-based age estimation 
in cognitively normal population using more than 6,000 scans. The deep learning neuroimaging 
models classified AD and estimated age with high accuracy, and also revealed regional patterns 
conforming to neuropathophysiology. The deep learning derived MRI measure demonstrated 
potential clinical utility, outperforming other AD pathology measures and biomarkers. In addition, 
I explored the utility of deep learning on positron emission tomography (PET) data for AD 
diagnosis and regionality analyses, further demonstrating the broad utility and generalizability of 
the method. 
 Finally, I introduced a technique enabling CBV generation retrospectively from clinical 
contrast-enhanced scans. The derivation of meaningful functional measures from such clinical 
scans is only possible through calibration to a reference, which was built from the largest collection 
of research CBV-fMRI scans from our lab. This method was validated in an epilepsy study and 
demonstrated the potential to enhance the utility of CBV-fMRI by enriching the CBV-fMRI 
dataset. This technique is also applicable to AD and normal aging studies, and potentially enables 
deep learning based analytic approaches applied on CBV-fMRI with similar pipelines used in 
structural MRI. 
 Collectively, this thesis demonstrates how mechanistic and diagnostic information on brain 
disorders can be extracted from large-scale neuroimaging data, using both classical statistical 
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Neuroimaging, more specifically brain imaging, is the technique to image the structure and 
function of the brain. Neuroimaging serves as a critical tool in neurological clinical practice as 
well as neuroscience investigations. Some of the commonly used neuroimaging modalities are 
shown in Figure 1-1. In this thesis, I will mainly focus on two of the modalities: T1 weighted 
structural MRI and steady state exogenous contrast cerebral blood volume functional magnetic 
resonance imaging (CBV-fMRI). 
 
Figure 1-1. Sample neuroimaging modalities, with focuses on T1w structural MRI and CBV-
fMRI in this thesis work. 
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1.1.2 Cerebral blood volume 
Functional neuroimaging refers to studying the function and metabolism of the brain using imaging 
method, and broadly covers different variants of fMRI, positron emission tomography (PET), 
single-photon emission computed tomography (SPECT), electroencephalogram (EEG), 
magnetoencephalography (MEG), etc., among which fMRI is especially suitable to study brain 
regional functions because of its high spatial resolution and other practical aspects. FMRI can be 
roughly categorized into CBV, cerebral blood flow (CBF), Blood-oxygen-level dependent (BOLD) 
fMRI based on different underlying imaging measures. 
 Cerebral blood volume is a measure of the quantity of blood in a unit of tissue. A variant 
of MRI generated from steady-state exogenous contrast brain imaging using intravenous contrast 
agent (e.g. gadolinium-based contrast agents, GBCAs) can be used to generate CBV values on a 
voxel by voxel basis (Lin, Celik, & Paczynski, 1999). Values of percentage CBV extracted from 
these scans have been shown to reflect a basal state of cerebral activity, and CBV has been shown 
to strongly correlate with 18-flourodeoxyglucose PET (FDG-PET) measuring glucose metabolism 
(González et al., 1995). 
 CBV-fMRI enjoys the advantage of high spatial resolution, compared with other fMRI 
modalities, which is crucial to investigate complex neuroanatomical circuits such as the 
hippocampal subfields. Our lab has utilized CBV-fMRI to study the hippocampal dysfunctions in 
various brain disorders including Alzheimer’s disease (Khan et al., 2014), schizophrenia (Schobel 
et al., 2013), Huntington’s disease (Lewandowski et al., 2013), and also normal aging (Brickman 




1.1.3 Structural measurement of brain 
Besides brain function and metabolism measured using CBV-fMRI and other functional 
neuroimaging modalities, the structural measurement of brain is also crucial to phenotype the brain 
pathophysiology, as it reflects the volume and composition of various cellular elements. Among 
different imaging modalities to quantify brain structures, I mainly focus on T1-weighted structural 
MRI, which is one of the most widely available and standardized imaging modalities and 
commonly has high spatial resolution and large contrast to noise ratio (CNR). 
 
1.1.4 Alzheimer’s disease and normal aging 
Alzheimer’s disease (AD) is a progressive neurodegenerative disease accounting for the majority 
cases of dementia (Alzheimer's Association, 2018), there are more than 50 million people living 
with dementia worldwide (Patterson, 2018). AD patients present progressive metabolic changes 
and atrophy in brain regions. Neurofibrillary tangles (NFTs) starting from entorhinal cortex (EC) 
or more focally transentorhinal cortex (TEC) characterize the early stage of AD according to 
postmortem studies (Braak & Braak, 1991). Amyloid, tau, and neurodegeneration are the major 
categories of AD biomarkers (Clifford R. Jack et al., 2018). 
 Normal aging in the context of this thesis refers to age-related changes in the brain that 
occur independent of any brain diseases. And the underlying pathophysiology is primarily 
dendritic spine loss without neuronal death (Morrison & Hof, 1997). Hippocampus is a subcortical 
structure heavily implicated in normal aging (Burke & Barnes, 2006; Scott A Small, 2011). 
Prefrontal cortex is another major region involved in normal aging (Gazzaley, Cooney, Rissman, 




1.1.5 CBV-fMRI studies on regional vulnerability in Alzheimer’s disease and 
normal aging 
Prior studies in the lab have pinpointed transentorhinal cortex as the vulnerable region in 
Alzheimer’s disease (Khan et al., 2014) and dentate gyrus (DG) as the vulnerable region in normal 
aging (Brickman et al., 2014) in the hippocampal formation using CBV-fMRI. Pioneering and 
impactful in our understanding of the underlying pathophysiology of Alzheimer’s disease and 
normal aging, the findings from these prior studies could still be validated and extended using 
larger-scale datasets and different measurements such as structural measures. 
 
1.1.6 Large-scale neuroimaging 
There are increasing high-quality large-scale neuroimaging datasets with the advancement of MRI 
hardware, data storage, and the continuous efforts of numerous investigators. Some of the 
prominent projects with well-characterized participants include Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) 1 , the Washington Heights-Hamilton Heights-Inwood 
Community Aging Project (WHICAP), etc. Over the years, our lab has collected the largest 
collection of research CBV-fMRI scans. And there are numerous large-scale studies focusing on 
other neurological diseases not listed here. These large-scale neuroimaging datasets greatly enrich 
the study population and cover more clinical and neurophysiological heterogeneity, allowing not 
only more reliable validation studies, but also more practical biomarker and diagnostics 




development. It should be noted that, “large-scale” itself is a relative term that depends on the 
availability of the data modality, and is heuristically defined in (Fritsch et al., 2015) as more than 
100. 
 
1.1.7 Deep learning 
Besides the interest of mechanistic understanding of brain disorders and normal aging, large-scale 
datasets also empower computer-aided imaging-biomarker discovery for diagnosis. Recent years 
have witnessed the rise of deep learning techniques (Goodfellow, Bengio, & Courville, 2016; 
LeCun, Bengio, & Hinton, 2015), the core of current artificial intelligence (AI) techniques. Deep 
learning, aka deep neural network, relies on the deep hierarchical representation enabled by 
efficient algorithm and hardware and large-scale datasets, and has revolutionized many aspects of 
research and everyday life including medical imaging (Gulshan et al., 2016; Hazlett et al., 2017). 
In the context of deep learning, “large-scale” manifests in both data and feature dimensions. Deep 
convolutional neural network (CNN) is the dominant class of deep learning model in image 
recognition field, and characterized by its efficiency at extracting patterns from images with 
weight-sharing and local connectivity properties, inspired by some early neuroscience studies in 
visual cortex (Hubel & Wiesel, 1962, 1968). And besides the superior discrimination performance, 
the interpretability of the machine learning models is receiving increasing attention (Lipton, 2018), 
especially in the medical diagnosis domain. It is possible, through interpretability analysis, the 
highly accurate machine learning model trained with broad population distribution can extract and 





The advent of large-scale datasets, together with high-performance computing hardware and 
advanced machine learning algorithms, have opened up many new possibilities in neuroimaging 
research. In this thesis, I focus on the utilities of large-scale neuroimaging and demonstrate their 
feasibility and effectiveness as applied in Alzheimer’s disease and normal aging studies: 1) 
validation and extension of prior studies using large-scale dataset; 2) neuroimaging based 
diagnosis and regionality analyses empowered by large-scale datasets and advanced deep learning 
algorithms; 3) enhancement of cerebral blood volume (CBV) fMRI utility with retrospective CBV. 
 
1.3 Specific aims 
More specifically, I target three specific aims in this thesis, which correspond to the three utilities 
of large-scale neuroimaging datasets listed in the motivation section. 
 Specific Aim 1 investigates large-scale validation and extension of prior studies using 
classical image processing and statistical methods, including 1) a large-scale structural 
neuroimaging study of AD that validates and localizes more reliably and with better anatomical 
resolution the AD-vulnerable region, and a structural neuroimaging study of healthy APOE ε4 
homozygous subjects screened from a large-scale community-based study following a similar 
approach; 2) a large-scale joint functional and structural neuroimaging study of normal aging 
covering age 20-70s, and a structural neuroimaging study of normal aging covering the full age-
span, with the elder group screened from a large-scale clinic-based study ensuring no evidence of 
AD using both longitudinal follow-up and CSF biomarkers evidences. 
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 Specific Aim 2 focuses on deep learning neuroimaging. Without the time- and labor-
consuming MRI post-processing and manual editing steps, the scale of the dataset can be further 
boosted. In this study, I proposed an AD diagnosis method using a 3D convolutional neural 
network model trained and evaluated on ~4,600 structural MRI scans and investigated a series of 
novel regionality analyses. This study constitutes a general analytic stream/framework, which was 
followed to perform a study on age estimation in normal aging population using more than 6,000 
structural MRI scans. I demonstrated that a deep learning neuroimaging approach can achieve high 
classification and regression performance and also reveals patterns conforming to 
neuropathphysiological priors. The deep learning derived MRI measure demonstrated potential 
clinical utility, outperforming other AD pathology measures and biomarkers. In addition, I 
explored the utility of deep learning on PET data for AD diagnosis and regionality analyses, further 
demonstrating the broad utility and generalizability of the method. 
 Specific Aim 3 introduced retrospective CBV generation from clinical contrast-enhanced 
scans. The derivation of meaningful functional measures from such clinical scans is only possible 
through calibration to a reference, which was built from the collection of research CBV-fMRI 
scans from our lab. Validated in an epilepsy study, the method is also applicable to AD and normal 
aging studies. This technique is also applicable to AD and normal aging studies, and potentially 
enables deep learning based analytic approaches applied on CBV-fMRI with similar pipelines used 





This thesis work has the potential to advance neuroimaging studies using large-scale datasets by 
demonstrating the feasibility and utility of extracting mechanistic and diagnostic information on 
brain disorders using both classical statistical and advanced machine learning methods. Large-
scale studies could validate and extend the findings in prior studies in a more reliable and 
generalizable way. Large-scale datasets also enable studying low prevalence conditions and 
subjects screened with stringent criteria, through large well-characterized populations. Deep 
learning neuroimaging demonstrates superior performance in AD classification and age estimation, 
enjoys practical advantages, and is supported by the neuropathological priors, thus could 
potentially be developed into a practical multi-faceted neurological disease and normal aging 
evaluation system. The large-scale collection of CBV-fMRI scans makes it possible to mine 
underutilized clinical contrast-enhanced scans, and could greatly enhance the utility of CBV-fMRI, 




2 Specific Aim 1: Large-scale validation and extension of prior 
studies 
In this section, I mostly relied on classical image processing and statistical methods to perform 
mechanistic studies of AD and normal aging with large-scale neuroimaging datasets. 
 I performed a study localizing AD-vulnerable regions more reliably and with better 
anatomical resolution using data from more than 350 subjects. Following a similar approach, I 
investigated the structural characteristics of cognitively normal APOE ε4 homozygous subjects 
screened from a large-scale community-based study. 
 To study the neuroimaging signatures of normal aging, we performed a large-scale joint 
CBV-fMRI and structural MRI study covering age 20-70s, and a structural MRI study of normal 
aging covering the full age-span, with the elder group screened from a large-scale clinic-based 
study ensuring no evidence of AD using both longitudinal follow-up and CSF biomarkers 
evidences. 
2.1 Alzheimer’s disease 
2.1.1 Introduction 
2.1.1.1 Transentorhinal cortex 
Prior studies have pinpointed TEC as a vulnerable region in AD using CBV-fMRI, but because of 
the trade-off of CBV-fMRI in its high in-plane resolution (0.78 mm × 0.78 mm) and low slice 
thickness (3 mm), it would be less accurate when trying to interrogate the long axis, which also 
present specialization (Poppenk, Evensmoen, Moscovitch, & Nadel, 2013). We collected 
structural MRI scans with isotropic 1mm spatial resolution in a large-scale dataset comprised of 
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188 AD scans and 169 cognitively normal control scans from ADNI to localize the structurally 
AD-vulnerable region.  
 
2.1.1.2 APOE 
Apolipoprotein E (APOE) ε4 is one major genetic risk factor for AD. APOE ε4 homozygous 
subjects were shown to have medium-to-high risk of developing AD and low population 
prevalence (Scheltens et al., 2016). Studying the brain morphology of cognitively normal subjects 
in this high-risk group is important to understand the mechanism of the increased risk, 
disentangling from the effect of the developed AD pathology. Few studies investigate the 
cognitively normal elder APOE ε4 homozygous subjects because of the low prevalence. A number 
of previous studies on cognitively normal APOE ε4 carriers have mainly relied on middle-aged 
(Cacciaglia et al., 2018; Fennema-Notestine et al., 2011) and adolescent cohort (P. Shaw et al., 
2007) to exclude the confound of AD, but age is arguably another risk factor that might interact 
with genetic risk factors.  
 
2.1.2 Methods 
2.1.2.1 ADNI dataset 
The demographic information of the subjects used in the cortical thickness analysis to localize 
AD-vulnerable region is shown in Table 2-1. The details of the ADNI MRI acquisition protocols 
(Clifford R. Jack et al., 2008) can be found in the project website2. The T1w structural images 




were processed using FreeSurfer, generating individual cortical thickness maps (Bruce Fischl & 
Dale, 2000). The individual surfaces were registered into the FreeSurfer fsaverage space for inter-
subject analysis. At each vertex, I performed linear regression with thickness as the dependent 
variable, AD vs. cognitively normal diagnosis as testing variable, with gender and age as covariates. 
The t-values of the regression analyses were rendered as t-maps in difference spaces. 
Table 2-1. The demographic information of the subjects used in the analysis to localize AD-
vulnerable region. 
 AD (N=188) Normal (N=169) 
Age mean±std 75.18±7.50 75.64±5.18 
Gender M/F 99/89 83/86 
 
2.1.2.2 WHICAP dataset 
In a large well-characterized cohort from WHICAP study, we identified 7 cognitively normal 
APOE ε4 homozygous carriers from 383 cognitively normal subjects, who have stayed cognitively 
normal during the follow-up period. The demographic information can be found in Table 2-2. I 
carried out the analysis in a similar way as described in the previous section, where the testing 
variable is substituted to APOE ε4 homozygous carriers vs. others. 
Table 2-2. Demographic information of the subjects from WHICAP study used to investigate 
the structural cortical characteristics of healthy APOE ε4 homozygous subjects. 
 APOE ε4 homozygous carriers (N=7) Others (N=376) 
Age range 67.2 - 80.7 62.5 - 96.1 
Age mean  std 72.5  5.0 73.7  5.7 
Gender M/F 4/3 156/220 




2.1.2.3 Flat-map representation 
In this study, I also proposed using the flat-map representation of the cortical surface (Bruce Fischl, 
Sereno, & Dale, 1999; David C Van Essen, Drury, Joshi, & Miller, 1998). Flat-map is the most 
compact way to represent the cortex, which provides unbiased visualization of the whole cortex in 
one single view, with no discontinuity or distortion (e.g. foreshortening) especially at the margin 
of the view. This representation facilitates observation and summarization of results, identification 
of clustered parcellation of interest (POI) and the comparison of the anatomical locations and 
spatial extents of the effects across different analyses. It also has computational merits because of 
the 2D representation. An illustration is shown in Figure 2-1. 
 
Figure 2-1. An illustration of flat-map representation of human cortex. (Left) Multiple 3D 
views are required for the full view of brain surface. (Right) Flat-map instead provides an unbiased 





2.1.3.1 AD-vulnerable region 
The results of the cortical thickness analysis of AD vs. cognitively normal subjects are summarized 
in Figure 2-2. In the flat-map representation, there presents a very focal AD-related atrophy in the 
anterior lateral entorhinal region. The affected region is rendered in other spaces as well. This 
points to the precise location within the full range of trans-entorhinal cortex (Augustinack et al., 
2013) (indicated by the yellow arrows in the rightmost 3D surface space of Figure 2-2) that is 
especially vulnerable in AD pathology. And facilitated with the flat-map representation, there are 
other interesting observations, e.g. the involvement of temporal, frontal, and parietal lobes and the 
relative sparing of primary motor, sensory, visual cortices. 
 
Figure 2-2. Cortical thickness analysis of AD vs. cognitively normal subjects. From left to right 
are the raw t-map and the thresholded t-map in the flat-map space, and the t-map in the anatomical 
space and the 3D surface space. In the 3D surface map, the cyan color indicates amygdala, the 
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yellow arrows point to the full range of transentorhinal cortex (Augustinack et al., 2013), the AD 
effect localizes to the anterior TEC at the level of amygdala. 
 
2.1.3.2 Structural characteristics of healthy APOE ε4 homozygous subjects 
The results of the cortical thickness analysis of healthy APOE ε4 homozygous carriers in the left 
hemisphere are summarized in Figure 2-3. There are two clusters with significant lower thickness 
that characterize the healthy APOE ε4 homozygous subjects: one is in superior frontal cortex, and 
the other is in anterior entorhinal cortex, as shown. 
 
Figure 2-3. Cortical thickness analysis of healthy APOE ε4 homozygous carriers. From left 
to right are the raw t-map and the thresholded t-map at flat-map space, and the t-map in the 
anatomical space and 3D surface space. There are two significant clusters: one in superior frontal 
cortex, the other in anterior entorhinal cortex. In the 3D surface space, the cyan color indicates 





2.1.4.1 AD-vulnerable region 
The cortical thickness analyses pinpoint the transentorhinal cortex at the level of amygdala along 
the long axis that is prominent in AD pathology, see Figure 2-2. This observation helped provide 
evidence for further immunoblotting analysis in ex vivo human brain tissue samples, as shown in 
Figure 2-4. 
 
Figure 2-4. The neuroimaging finding helped guide molecular analysis of ex vivo brain tissue 
in AD-vulnerable region. (Left) Pixels that show the greatest and most reliable volumetric loss 
compared to controls are indicated in yellow/red. The TEC defect is shown on a coronal MRI slice. 
(Right) A representative human postmortem brain tissue slice, matching the precise anatomical 
coordinates of the neuroimaging finding, with a higher magnification illustrating the subregions 
of the entorhinal cortex isolated for protein profiling:  the TEC, the lateral EC (LEC), intermediate 




2.1.4.2 Mechanistic implications from the healthy APOE ε4 homozygous subjects analysis 
A previous study on healthy middle age subjects has shown significantly thinner cortex in superior 
frontal region of APOE ε3/4 group compared with ε3/3 group, with no significant effects of ε4 
status on any temporal lobe measures (Fennema-Notestine et al., 2011). Whereas, a study in 
healthy adolescents reported thinner left entorhinal cortex in APOE ε4 carrier and suggested that 
the thinner entorhinal cortex in ε4 carriers might contribute to the risk of Alzheimer’s disease (P. 
Shaw et al., 2007). In our analysis of elderly healthy APOE ε4 homozygous subjects, we observed 
significantly thinner regions in both superior frontal region and entorhinal cortex region. These 
results might imply complex genetic-age interaction. 
 For APOE gene, the regions with the highest expression levels are entorhinal cortex, 
parahippocampal cortex and temporal pole according to the data from Allen Brain Atlas3 and the 
analytic method developed in (French & Paus, 2015). And a previous mouse study has reported 
ApoE4 protein exacerbates tau-mediated neurodegeneration (Shi et al., 2017). Taking into 
consideration the postmortem study of neurofibrillary tangles, where tauopathy starts from 
transentorhinal cortex (Braak & Braak, 1991), the observations might provide evidence explaining 
the risk of Alzheimer’s disease in APOE ε4 carrier from a genetic-molecular co-localization point 
of view. 
  




2.2 Normal aging  
2.2.1 Introduction 
Extending prior studies in normal aging, we performed a more thorough functional and structural 
investigation of normal aging using data from an aging study our lab recently completed, in which 
both CBV and volume were mapped in over 100 carefully-screened cognitively normal individuals 
spanning 20-72 years of age (Figure 2-6). This cohort will be denoted as Columbia cohort 
hereinafter in this chapter. We analyzed the age-related changes in both CBV and volume. 
 We further relied on a mouse study to establish an MRI-based profile reflective of dendritic 
spine loss, and provide mechanistic evidence for the findings in the human normal aging study. 
 We further set out to broaden the age-span to older subjects, which is important for 
understanding how the brain is affected throughout the full age span. We relied on longitudinal 
clinical follow-up and CSF biomarker data to ensure the study population is free of AD. 
 Collectively, the studies show that the dentate gyrus within the hippocampus and the 
inferior frontal gyrus across the cortex are the two brain regions differentially affected by normal 
aging structurally and functionally and fulfil the MRI-based profile of dendritic spine loss, 
suggesting dendritic spine loss as the underlying pathophysiology. The entorhinal cortex, a region 
most vulnerable to AD, turned out to be the region most resistant to normal aging. 
2.2.1.1 Concordant changes in functional and structural MRI reflect dendritic spine loss 
Both functional and structural neuroimaging should be sensitive to dendritic spine loss in normal 
aging, since dendritic spines are known to have high metabolic needs (Z. Li, Okamoto, Hayashi, 
& Sheng, 2004). This is validated by various functional imaging studies in both cerebral cortex 
(de Leon et al., 2001; Gazzaley et al., 2005; Martin, Friston, Colebatch, & Frackowiak, 1991) and 
18 
 
hippocampus (Brickman et al., 2014; Pavlopoulos et al., 2013; Scott A Small, Chawla, Buonocore, 
Rapp, & Barnes, 2004; Yassa, Mattfeld, Stark, & Stark, 2011). Structural imaging is also expected 
to be sensitive to spine loss because of the space-occupying spine-related cell elements. Studies 
have shown that variables derived from structural MRI are sensitive to dendritic spine loss 
(Kassem et al., 2013; Keifer Jr et al., 2015).  
 While both functional and structural imaging could be sensitive to dendritic spine loss, they 
are not necessarily specific. This is particularly the case for structural measures, as there are 
numerous elements that can contribute to volumetric changes independent of spine loss. And 
neuronal death is a neuropathological process that can drive decreases in both functional and 
structural measures. We hypothesized that, in the absence of neuronal death, a concordant change 
in functional and structural measures might represent a neuroimaging profile reflective of dendritic 
spine loss. This hypothesis was validated in an unilateral whisker cutting experiment in young 
mice led by Dr. Jia Guo, where the intervention induces dendritic spine loss in select barrel cortex 
layers (Y. Zuo, Yang, Kwon, & Gan, 2005).  
 In the mouse study, CBV in each layer was measured in two ways. The first is %CBV, 
which is an estimate of CBV density within a unit volume of brain, similar to density estimates 
used in prior functional imaging studies (de Leon et al., 2001; Khan et al., 2014). However, as 
established for other functional readouts of the brain, for example neurons or synapses, density 
measures introduce potential biases (Kempermann, Kuhn, & Gage, 1997; Morrison & Hof, 1997; 
Napper, 2018; West, 1999). When possible, “total” measurements are proven superior, typically 
generated by multiplying density and regional volume (Kempermann et al., 1997; West, 1999). 
We therefore used this approach to also generate total CBV (tCBV) for each layer. Only layers 
containing synapses have a loss in both CBV and volume in the contralateral barrel cortex after 
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unilateral whisker cutting, and have a correlation between both measures. And as anticipated, 
tCBV was found superior to %CBV in mapping these changes.  
 Together, we concluded that when it is known that a condition is not associated with 
neuronal death, as is the case with normal aging (Morrison & Hof, 1997), an MRI-based profile 
reflective of dendritic spine loss should fulfill two criteria: a reduction in regional tCBV and 
regional volume, and a correlation between both MRI-based variables.  
 We relied on these insights from the mouse findings to map correlates of dendritic spine 
loss in normal aging in human. We found dentate gyrus and the inferior frontal gyrus were both 
differentially affected by normal aging structurally and functionally and showed concordance, 
suggesting dendritic spine loss as the underlying neurophysiological mechanism of the age-related 
changes in these two regions. 
2.2.1.2 Necessity and method to exclude the confound of AD 
For normal aging studies, one challenge has been excluding AD, especially preclinical AD which 
occurs years before its clinical onset and is usually undetectable by conventional clinical measures 
(Sperling et al., 2011). The AD confound is particularly acute when attempting to cover the tail 
end of the age-span. Preclinical AD’s prevalence is estimated to begin its dramatic age-related rise 
during the 8th - 9th decades of life (Brookmeyer, Abdalla, Kawas, & Corrada, 2018), with the 
estimated prevalence of preclinical AD reaching as high as 50%. 
 Only a few subjects of the Columbia cohort were in the high prevalence age range, and the 
fact that the entorhinal cortex was found to be unaffected by aging, supports the interpretation that 
the Columbia cohort was not dominated by subjects with occult AD dementia. 
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 To investigate an older cohort in whom the AD confound can be excluded, we turned to 
the ADNI. ADNI includes a large population of cognitively normal participants who have been 
followed longitudinally and who have, among extensive clinical and neuropsychological testing, 
CSF biomarkers of AD. While ADNI does not acquire high-resolution functional imaging data, it 
does acquire high resolution structural MRI. We derived volumetric measurements in participants 
who met strict clinical and CSF biomarker criteria against AD. Two CSF cutoffs were established 
by ADNI (L. M. Shaw, Figurski, Waligorska, & Trojanowski, 2016), one that relies on CSF A 
alone and the other that relies on a combination of CSF tau and A. We opted for the later, as 
recent studies have shown that AD-associated elevations in CSF tau, and tau pathology itself, are 
strong determinants of regional dysfunction and atrophy (Tarawneh et al., 2015; Thaker et al., 
2017). In addition, we also performed analyses using tau/Aβ as a continuous covariate instead of 
setting a binary grouping using the cut-off value. 
 
2.2.2 Methods 
2.2.2.1 Columbia cohort 
For Columbia cohort, subjects are healthy adults between age 20 and 72, recruited from the 
Columbia University Medical Center/New York Presbyterian Hospital campus. MRI acquisition 
was part of a Columbia University Medical Center Institutional Review Board approved study, 
with explicit written consent obtained from each participant. The data selection process is 
illustrated in the left panel of Figure 2-5, with the demographic information of the CBV-fMRI 
dataset summarized in Figure 2-6, the demographic information of the structural MRI dataset 




Figure 2-5. Dataset selection process for the Columbia and ADNI cohorts in the normal aging 
study.  
 




2.2.2.2 Cross-sectional cohort of normal aging elderlies from ADNI 
As described in the introduction of the chapter, we adopted two strategies to deal with the AD 
confound as indicated best by the composite of CSF tau/Aβ ratio. From ADNI, we identified 80 
subjects who were cognitively normal at baseline and stayed normal during at least 4 years of 
clinical follow-up and who have baseline CSF biomarker. In the first analysis, we only included 
the 52 subjects who were CSF biomarker negative for AD, using the combined tau/Aβ cutoff 
(tau/Aβ < 0.39) (L. M. Shaw et al., 2016; L. M. Shaw et al., 2009). The demographic information 
of the 52 subjects is summarized in  
Figure 2-7. In another analysis, we included all 80 subjects and included the tau/Aβ ratio as a 
covariate. The data selection process is illustrated in the right panel of Figure 2-5.  
 
Figure 2-7. Demographic information of the subjects in the structural normal aging study 
covering 20-85 years old. 
 
2.2.2.3 Longitudinal cohort of normal aging elderlies from ADNI 
From the 80 subjects in the cross-sectional analysis, we further identified 62 subjects who have 
five longitudinal MRI scans at baseline, month 6, 12, 24, and 48 for longitudinal analysis. In the 
similar manner as the cross-sectional analysis, we identified 40 subjects who were CSF biomarker 
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negative for AD using the tau/Aβ cutoff. And additionally, we included all 62 subjects and 
included the tau/Aβ ratio as a covariate in the analysis. 
 
2.2.2.4 MRI acquisition 
For the CBV-fMRI, we used a steady-state contrast enhanced CBV technique as previously 
described (Brickman et al., 2014; Khan et al., 2014). MRI scans were acquired with a Philips 
Achieva 3.0 T MRI scanner using an 8-channel SENSE head coil. In each scan session, a T1-
weighted structural scan (TR = 6.7 ms, TE = 3.1 ms, FOV = 240 × 240 × 192 mm3, voxel size = 
0.9 × 0.9 × 0.9 mm3) was first acquired using a Turbo Field Echo (TFE) gradient echo (GRE) 
sequence; a pair of un-scaled T1-weighted images (TR = 7 ms, TE = 3 ms, FOV = 240 × 240 × 
162 mm3, voxel size = 0.68 × 0.68 × 3 mm3) were acquired afterwards with a bolus injection of 
gadolinium contrast agent in between. 
 
2.2.2.5 MRI processing 
The T1-weighted structural images were processed using FreeSurfer, generating cortical 
parcellation (Desikan et al., 2006; B. Fischl et al., 2004) and hippocampal subregions segmentation 
(Iglesias et al., 2015) in the individual space. The list of cortical regions can be found in the 
parcellation protocol documented in (Desikan et al., 2006). The primary hippocampal subregions 
labeled include presubiculum (PRESUB), subiculum (SUB), CA1, CA3, CA4 (hilus), granule cell 
molecular layer of DG (DG), molecular layer of subiculum and CA fields (MLSUBCA).  
 CBV-fMRI processing followed the steps applied in previous studies (Brickman et al., 
2014; Khan et al., 2014) and included registration of the pre-contrast and the post-contrast T1-
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weighted scans, subtraction of the co-registered post-contrast and pre-contrast scans, and CBV 
value normalization with the mean signal in the superior sagittal sinus. The raw CBV values 
are %CBV measures in a unit voxel. 
 Individual structural images were registered into template space with a symmetric 
diffeomorphic algorithm using ANTS (Avants et al., 2011). Individual CBV images were linearly 
registered into the individual structural image space. The CBV images were registered to the 
template space with the transformation field composed of the linear transformation matrix and the 
diffeomorphic transformation field.  
 In ROI analyses, total CBV (tCBV) measures the total amount of cerebral blood volume in 
an anatomically defined ROI and was calculated as the product of the regional %CBV density and 
the ROI volume. In voxel/vertex-based analyses, tCBV measures the voxel/vertex-wise local total 
amount of cerebral blood volume and is the voxel/vertex-wise product of CBV and volumetric 
measures. 
 
2.2.2.6 Image Analysis 
2.2.2.6.1 Total CBV voxel-based analysis in the hippocampus 
For each voxel, the tCBV value is the product of %CBV and the Jacobian determinant, which 
measures the relative volume change warping from unit volume element into the template space. 
Voxel-wise linear regression with age as regressor, gender and ICV as covariates was performed 
using SPM84. The results were thresholded at p < 0.05 and spatial cluster size larger than 10.  




2.2.2.6.2 Total CBV vertex-based analysis in the cortex 
Vertex-based analysis was used for cortical tCBV analysis. Individual CBV-fMRI images were 
registered into individual structural image space using linear registration. The cortical surface in 
individual structural image space was reconstructed using FreeSurfer (Dale, Fischl, & Sereno, 
1999). The co-registered CBV-fMRI image was projected onto the reconstructed cortical surface 
along the surface normal with projection fractions from 0 to 1 in the step of 0.1. The projected 
maps were then averaged into a single map generating robust measures of surface-based cortical 
CBV. The individual surfaces along with the projected CBV maps were registered into the 
FreeSurfer fsaverage space for inter-subject analysis. Cortical volume maps in the same space 
were generated using FreeSurfer, where the volume measure at each vertex is the volume of the 
local truncated tetrahedron. The tCBV at each vertex is the product between the %CBV and 
volume. Vertex-wise linear regression with age as regressor, gender and ICV as covariates, was 
performed using custom scripts. The results were thresholded at p < 0.01 and spatial cluster size 
larger than 500. 
2.2.2.6.3 ROI analysis 
The cortical parcellation and hippocampal subregion segmentation label maps were registered into 
the CBV-fMRI image space with the transformation matrix from registering individual CBV 
image into the individual structural image space. Regional %CBV is the average %CBV within 
each ROI. Regional tCBV is the product of the regional %CBV and the ROI volume. Linear 
regression with age as regressor, gender and ICV as covariates was performed for each ROI. It has 
to be noted that the frontal pole labeled in the segmentation protocol was not fully covered in a 
small portion of the CBV-fMRI scans because of the field of view (FOV) thus were not included 
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in the results. In the volume ROI analyses, for each ROI, I used linear regression with ROI volume 
as dependent variable, age as regressor, gender and ICV as covariates. 
2.2.2.6.4 Longitudinal ROI analysis 
In the longitudinal volume ROI analysis, I performed repeated measure ANOVA with baseline 
age, gender, ICV, and baseline tau/Aβ ratio as covariates; and in the other analysis with subjects 
below tau/Aβ cut-off, I performed repeated measure ANOVA with baseline age, gender, ICV as 




In the exploratory analysis, the most reliable age-related changes were observed in the left brain, 
similar to what has been previously described (Chetelat et al., 2013; de Leon et al., 2001; Martin 
et al., 1991). We, however, cannot exclude technical reasons for this lateralizing effect. All 
analyses were conducted on measurements derived from the left brain. 
2.2.3.1 Brain regions vulnerable and resistant to normal aging from 20-72 years of age 
2.2.3.1.1 CBV-fMRI 
Results revealed that across the cortex the most reliable age-related tCBV decrease was observed 
in the vicinity of the inferior frontal gyrus (Figure 2-8A). For the complimentary ROI analysis, the 
only two regions that showed significant age-related CBV decreases at significance level α = 1e-
6, after applying a Šidák correction, were two constituent subregions of the inferior frontal gyrus 
(pars orbitalis: t = -6.28, p = 1.04e-8; pars triangularis: t = -6.08, p = 2.61e-8, two-tailed, N = 98) 
(Figure 2-8B). Unexpectedly, the entorhinal cortex was the cortical region that was least affected 
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by aging (t = 0.411, p = 0.682, two-tailed, N = 98) (Figure 2-8B). Within the hippocampus, the 
most reliable age-related decline was observed in the dentate gyrus (Figure 2-8C). For the ROI 
analysis, the dentate gyrus was found to be the dominant site of age-related CBV decline (t = -
6.19, p = 1.53e-8, two-tailed, N = 98) (Figure 2-8D). 
 
Figure 2-8. Mapping normal aging with CBV-fMRI from 20-72 years of age. (A) A vertex-
based analysis of the cortex (VBA; left image) and a region-of-interest analysis across cortical 
regions (ROI; right image) identified the greatest age-related decline of cerebral blood volume 
(CBV) in the inferior frontal gyrus. (B) The t-value distribution of age-related CBV decline across 
cortical regions shows that two regions of the inferior frontal gyrus (indicated in red, the pars 
orbitalis and the pars triangularis) are most reliably vulnerable to aging. The entorhinal cortex 
(indicated in blue) was found most resistance to aging. The dashed red line indicates the t-value 
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threshold at α = 0.05 adjusted for Šidák multiple comparison. (C) A voxel-based analysis of the 
hippocampus (VBA; left image) and a region-of-interest analysis across hippocampal regions (ROI; 
right image) identified the greatest age-related CBV decline in the dentate gyrus. (D) The t-value 
distribution of age-related CBV decline across hippocampal regions, shows that the dentate gyrus 
(indicated in red) is most reliably vulnerable to aging. The dashed red line indicates the t-value 
threshold at α = 0.05 adjusted for Šidák multiple comparison. 
 The corresponding analysis results using percentage CBV are shown in Figure 2-9, 
revealing similar localization results. 
 
Figure 2-9. Mapping aging with CBV-fMRI from 20-72 years of age using percentage CBV. 
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2.2.3.1.2 Volumetric MRI 
For volumetry results, across the cortex, subregions of the inferior frontal gyrus were found 
significantly associated with aging (pars orbitalis: t = -7.50, p = 2.62e-11; pars triangularis: t = -
6.88, p = 5.38e-10, two-tailed, N = 104), although, unlike for CBV, their volumes were not the 
ones most reliably affected by aging (Figure 2-10). As with CBV, the entorhinal cortex was the 
cortical region least affected by aging (t = -0.445, p = 0.657, two-tailed, N = 104). Within the 
hippocampus, the dentate gyrus was again the region differentially affected by aging (t = -5.04, p 
= 2.08e-6, two-tailed, N = 104). 
 
Figure 2-10. Mapping normal aging with volumetric MRI from 20-72 years of age. The t-
value distribution of age-related decline in volume, measured by structural MRI, across cortical 
regions. While not most reliably affected, volumes of regions of the inferior frontal gyrus 
(indicated in red) decline significantly with age. The volume of the entorhinal cortex (indicated in 
blue) was found most resistance to aging. The dashed red line indicates the t-value threshold at α 
= 0.05 adjusted for Šidák multiple comparison.  
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2.2.3.1.3 CBV-Volume relationships 
Guided by the mouse study, we found a significant correlation between tCBV and volume in the 
dentate gyrus (r = 0.524, p = 3.14e-8, two-tailed, N = 98) and the inferior frontal gyrus (r = 0.563, 
p = 2.00e-9, two-tailed, N = 98) (Figure 2-11), and so both regions fulfill the criteria for MRI-
based profile reflective of dendritic spine loss. In an exploratory analysis, we found that some 
regions fulfilled one criterion but not both, e.g. the paracentral lobule showed significant age-
related volume reduction (t = -4.48, p = 2.13e-5, two-tailed, N = 98) but not tCBV reduction (t = -
0.123, p = 0.902, two-tailed, N = 98) or a reliable correlation between tCBV and volume (r = 0.054, 
p = 0.601, two-tailed, N = 98) (Figure 2-11). The correlation values of the whole set of regions can 
be found in Figure 2-12. 
 
Figure 2-11. The relationship between volumetric MRI and CBV-fMRI. A significant 
concordant relationship between CBV and volume is observed for the dentate gyrus and the 
inferior frontal gyrus, consistent with the MRI profile of dendritic spine loss, but not for the 




Figure 2-12. A summary graph of the partial correlation coefficients of tCBV versus age, 
volume versus age, and tCBV versus volume. Gender and ICV were included as covariates. The 
dashed red line indicates the correlation coefficient threshold at α = 0.05 adjusted for Šidák 
multiple comparison. 
 
2.2.3.2 Brain regions vulnerable and resistant to normal aging from 62-85 years of age 
We generated cortical and hippocampal volumes as with the Columbia cohort and then applied the 
same linear regression model to each volume (Figure 2-13). Across the cortex, regions of the 
inferior frontal gyrus were found unaffected by aging in this age-span, but here again the entorhinal 
cortex was one of the regions least affected by aging. Within the hippocampus, the dentate gyrus 
was again the region most reliably affected by aging (t = -2.37, p = 0.0217, two-tailed, N = 52), 
however, likely because of the constrained age-range, the effect in the dentate gyrus did not meet 
the Šidák-corrected threshold for significance at α = 0.05. The regional pattern was similar in the 




Figure 2-13. Mapping normal aging with volumetric MRI in AD-free subjects from 62 - 85 
years of age. The t-value distribution of age-related decline in volume across cortical and 
hippocampal region, shows that the dentate gyrus (indicated in red, right graph) is most vulnerable 
to aging and the inferior frontal gyrus (indicated in red, left graph) is not reliably associated with 
aging. The entorhinal cortex (indicated in blue, left graph) is least affected by aging. The dashed 




Figure 2-14. Mapping normal aging with volumetric MRI from 62-85 years of age with 
tau/Aβ as covariate. The t-value distribution of age-related volume decline across cortical and 
hippocampal region with tau/Aβ as covariate, from 62-85 years of age, shows that the dentate 
gyrus (indicated in red, right graph) is most vulnerable to aging (although not crossing threshold 
of multiple comparisons) and the inferior frontal gyrus (indicated in red, left graph) is not reliably 
associated with aging. The entorhinal cortex (indicated in blue, left graph) is among regions least 
affected by aging. The dashed red line indicates the t-value threshold at α = 0.05 adjusted for Šidák 
multiple comparison. 
 
2.2.3.3 Longitudinal analysis of brain regions vulnerable and resistant to normal aging  
No region, including entorhinal cortex and dentate gyrus, showed significant longitudinal atrophy 
when controlling for the covariates (Figure 2-15, Figure 2-16). 
 
Figure 2-15. Mapping longitudinal age-related change with volumetric MRI from 62-85 
years of age with tau/Aβ as covariate. The p-value distribution of longitudinal age-related 
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volume decline across cortical and hippocampal regions with tau/Aβ as covariate, from 62-85 
years of age, illustrates that no region is showing reliable longitudinal age-related atrophy. The 
dashed red line indicates α = 0.05. 
 
Figure 2-16. Mapping longitudinal age-related change with volumetric MRI from 62-85 
years of age using tau/Aβ cutoff. The p-value distribution of longitudinal age-related volume 
decline across cortical and hippocampal regions with baseline tau/Aβ under cut-off threshold, from 
62-85 years of age, illustrates that no region is showing reliable longitudinal age-related atrophy. 
The dashed red line indicates α = 0.05. 
 
2.2.3.4 Brain regions vulnerable and resistant to normal aging across age span 
To map aging independent of AD across the full adult lifespan — from young adulthood, through 
midlife, to old age, we merged the Columbia cohort with the ADNI cohort, as shown in  
Figure 2-7. By mapping the age-related volumetric changes (Figure 2-17), the most remarkable 
result is that among all brain regions investigated, the entorhinal cortex is the region most 
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resistance to normal aging (t = 1.21, p = 0.227, two-tailed, N = 156). Not surprisingly, based on 
the previous analyses, the dentate gyrus was the hippocampal region most reliably affected by 
aging (t = -6.61, p = 6.24e-10, two-tailed, N = 156). The inferior frontal gyrus, while not the region 
most affected, was still found significantly affected by aging (pars orbitalis: t = -9.63, p = 1.99e-
17; pars triangularis: t = -7.67, p = 1.96e-12, two-tailed, N = 156). 
 
Figure 2-17. Mapping normal aging with volumetric MRI across the adult age-span. The t-
value distribution of age-related decline in volume across cortical and hippocampal region in AD-
free subjects across the full age-span, shows that the dentate gyrus (indicated in red, right graph) 
is most vulnerable to aging and the inferior frontal gyrus (indicated in red, left graph) is reliably 
associated with aging. The entorhinal cortex (indicated in blue, left graph) is the region least 
affected by aging. The dashed red line indicates the t-value threshold at α = 0.05 adjusted for Šidák 
multiple comparison. 
 We relied on the combined dataset to explore the trajectories of the dentate gyrus, the 
inferior frontal gyrus, and the entorhinal cortex across the full age-span. Interestingly, the 
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vulnerable regions appear to have different aging trajectories. While the age-related effect of the 
dentate gyrus worsens linearly across the full age-span (page = 1.25e-8), the inferior frontal gyrus 
was better modeled by a quadratic curve (page = 3.79e-4, page^2 = 1.81e-2) (Figure 2-18 A) than a 
linear model, where the effect of aging on this brain region appears to taper off during normal 
aging. The Akaike information criterion (AIC) of the quadratic regression model is lower than the 
linear regression model. The entorhinal cortex was best modelled as a flat line across the full age 
span (page = 0.261) (Figure 2-18 A).  
 
Figure 2-18. Trajectories of brain regions vulnerable and resistant to normal aging across 
the age-span. (A) The aging trajectory of dentate gyrus volume (left image) shows a linear decline 
across the age-span. The trajectory of inferior frontal gyrus volume (middle image) shows a 
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curvilinear decline. The trajectory of entorhinal cortex volume (right image) shows that it is 
unaffected by aging across the age-span. (B) A graphic summary of the two regions differentially 
vulnerable to normal aging, the dentate gyrus and the inferior frontal gyrus (red), and the region 
most resistant to normal aging, the entorhinal cortex (blue). 
 
2.2.3.5 Cross-sectional volumetric analyses in independent life-span normal aging studies 
I also performed cross-sectional volumetric analyses in three independent normal aging studies 
covering full adult age-span: Cam-CAN (Taylor et al., 2017), IXI, DLBS (Rodrigue et al., 2012). 
The results show similar patterns as those revealed in our cohort: dentate gyrus shows the most 
reliable age-related decrease within hippocampus, whereas the entorhinal show little age-related 
difference, IFG shows age-related decrease but superior frontal region shows the most reliable 
age-related decrease. The detailed results are included in the appendix A.1. 
 
2.2.4 Discussion 
In hippocampal formation, dentate gyrus was observed to be differentially vulnerable to normal 
aging. This agrees with previous imaging studies in non-human mammals (Moreno et al., 2007; 
Scott A Small et al., 2004), who develop age-related hippocampal dysfunction without the 
confound of AD, and also agrees with a recent post-mortem analysis of the disease-free human 
hippocampus (Adler et al., 2018). Across the cortex, the inferior frontal gyrus is the region most 
reliably affected by normal aging. This too agrees with previous studies (de Leon et al., 2001; 
Herholz et al., 2002; Kalkstein, Checksfield, Bollinger, & Gazzaley, 2011; Martin et al., 1991). 
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 Since we used a high-resolution CBV-fMRI technique, we were able to map, for the first 
time, age-related dysfunction in the dentate gyrus and inferior frontal gyrus in the same cohort. 
More importantly, since both the dentate gyrus and the inferior frontal gyrus fulfilled MRI-based 
criteria for spine loss, our findings provide primary evidence that age-related dendritic spine loss 
is the likely driver of dysfunction. 
 Both cohorts and the combined analysis provide definitive evidence that within the 
hippocampus the dentate gyrus is the region most dominantly affected by normal aging (Figure 
2-18). Findings from the ADNI cohort and the combined analysis suggest that age-related inferior 
frontal gyrus dysfunction tapers off in older age (Figure 2-18). However, as this observation was 
based only on volumetric information, we are less certain about this result. In both cohorts and in 
the combined analysis, the entorhinal cortex turned out to be the brain region differentially resistant 
to normal aging (Figure 2-18). We consider this a remarkable and unexpected finding, as this is 
the same region that is differentially vulnerable to AD (Braak & Braak, 1991; Gómez-Isla et al., 
1996; Khan et al., 2014; Miller et al., 2015). Our study is not the first to suggest that the entorhinal 
cortex is impervious to the effects of normal aging. This observation has been shown by studies 
imaging aging animal models (Moreno et al., 2007; Scott A Small et al., 2004), who are 
unconfounded by AD, that have focused on the hippocampal formation. But beyond the 
hippocampal formation, these previous studies did not perform a more comprehensive comparison 
of the entorhinal cortex to the multiple regions of the cortical mantle. 
 The results from the current study imply that normal aging targets our cognitive faculties 
more than others. Practically, the DG, IFG, EC function and structure and the related 
neuropsychological tests could be used collectively for cognitive aging subject screening and 
intervention read-out. We also make several propositions based on our findings: 1) the spatio-
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temporal pattern identified in the inferior frontal gyrus is potentially important to isolate molecular 
or cellular causes of age-related frontal cortex dysfunction; 2) the mechanisms that account for the 




3 Specific Aim 2: Alzheimer’s disease diagnosis and normal aging 
evaluation based on deep learning neuroimaging 
In this section, I performed a series of deep learning neuroimaging studies for diagnosis and 
regionality analyses. I proposed an AD diagnosis method using a 3D convolutional neural network 
model trained and evaluated on ~4,600 structural MRI scans and investigated a series of novel 
regionality analyses. The summary measures derived from the deep learning model has 
demonstrated potential clinical utility outperforming other AD pathology measures and 
biomarkers. 
 The AD deep learning study constitutes a general analytic framework, which I followed to 
perform a study on age estimation in normal aging using more than 6,000 scans. The deep learning 
neuroimaging approach demonstrated high classification and regression performance and also 
revealed regional patterns conforming to neuropathological priors. In addition, I explored the 
utility of deep learning on AD diagnosis and regionality analysis using PET, further demonstrating 
the broad utility and generalizability of the method. 
3.1 Alzheimer’s disease diagnosis 
3.1.1 Introduction 
3.1.1.1 AD diagnosis using MRI 
Because of the degenerative nature of Alzheimer’s disease and the current limit in therapy options, 
much research focuses on developing accurate diagnosis techniques. Our work applies deep 
learning to classify clinical diagnosis of AD from MRI, building upon recent studies that have 
demonstrated the usefulness of MRI in diagnosing AD and mild cognitive impairment (MCI) 
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(overlap with the corresponding prodromal stage of AD), and in categorizing biomarkers 
associated with neurodegeneration in AD (Clifford R. Jack et al., 2016). 
 Among different brain MRI modalities, T1-weighted structural MRI is one of the most 
widely acquired and enjoys the additional benefit of being relatively standardized across scanners 
and protocols. Consequently, diagnosis algorithms based on T1w structural MRIs are appealing as 
a potential tool to assist in disease screening given the wide availability of research scans for model 
training, and the ubiquity of MRI scanners in the world potentially enabling the rapid deployment 
of learned models. 
 
3.1.1.2 Deep learning 
Following applications in computer vision, deep learning techniques have emerged as effective 
tools for analysing medical images. On standard computer vision tasks such as classification 
(Krizhevsky, Sutskever, & Hinton, 2012), object detection (Girshick, 2015) and semantic 
segmentation (Long, Shelhamer, & Darrell, 2015), deep learning algorithms based on 
convolutional neural network (CNN) (LeCun et al., 1990) have achieved undisputed dominance. 
Over the last few years, these techniques have been widely applied in image-aided medical 
diagnosis. Successful applications of deep learning in medical imaging include segmenting 
electron microscopy images (Ronneberger, Fischer, & Brox, 2015), detecting diabetic retinopathy 
from 2D retinal fundus photographs (Gulshan et al., 2016), and recognizing skin cancer from 
photographs (Esteva et al., 2017). 
 However, learning from 3D scans, such as MRI, presents a number of additional challenges. 
While the number of voxels corresponding to the 3D volume representing a single patient can be 
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large, we still have just one label per scan, raising technical questions about how to prevent 
overfitting. However, since many brain disorders correspond to both focal and diffuse involvement 
and brain regions span 3D spaces, machine learning models capable of acting upon the whole 
volume are appealing. To that end, I explored the use of 3D convolutional neural networks for 
diagnosing Alzheimer’s disease, considering a variety of techniques and including some 
unconventional data sources in order to learn good representations without overfitting. Although 
3D CNNs have been explored in the medical imaging (Çiçek, Abdulkadir, Lienkamp, Brox, & 
Ronneberger, 2016; Dou et al., 2016; Milletari, Navab, & Ahmadi, 2016) for segmentations, they 
are relatively underutilized compared to 2D CNNs and thus best practices for deploying these 
models are less firmly established. 
 
3.1.1.3 Previous works 
This work was built upon several earlier works applying 3D CNNs to AD diagnosis, which were 
summarized below. Note that various papers address different datasets and different subsets even 
within the same cohort, making direct performance comparison across papers difficult. (Payan & 
Montana, 2015) proposed MRI-based AD diagnosis using 2265 scans from ADNI and achieved 
95.39% accuracy in AD vs. CN classification. The weights of the convolution filters are learned 
by training an autoencoder. While their study provides promising support of the efficacy of 3D 
CNNs for diagnosing AD from brain MRI, it leaves open many modelling questions. For instance, 
they consider only shallow networks consisting of a single convolutional layer, followed by a 
pooling operation and one fully-connected layer. Moreover, they leave the autoencoder-derived 
filters fixed, optimizing only the weights of the fully-connected layer on the AD classification task. 
Following similar ideas, (Hosseini-Asl et al., 2018) presented a model using unsupervised 
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autoencoding followed by (supervised) fine-tuning on a comparatively small dataset consisting of 
just 210 subjects (70 each for AD, MCI, CN) and showed impressive predictive performance with 
an area under the receiver operator characteristic (AUROC) of 0.993 and 99.3% accuracy in AD 
vs. CN classification. (S. Korolev, Safiullin, Belyaev, & Dodonova, 2017) apply a 3D network 
architecture, achieving AUROC of 0.88 with an accuracy of 79% in 50 AD and 61 CN subjects. 
They also attempt to interpret the network, introducing a heuristic technique for feature attribution. 
The method consists of generating predictions while obstructing various regions in the image to 
determine which regions impact the model’s predictions in multiple passes. A recent large-scale 
study (Wegmayr, Aitharaju, & Buhmann, 2018) proposed using 3D CNNs directly, training 
weights from scratch (no unsupervised pre-training) and achieved 86% accuracy in AD/CN 
classification in a merged ADNI+AIBL dataset consisting of 6618 scans from CN subjects and 
4476 scans from AD subjects. These studies demonstrate the promise of modern CNN 
architectures for extracting patterns from brain MRI. 
 Despite generating accurate predictions, deep learning has long been described as a black-
box. Studies have been proposed to interpret or explain the classifications produced by various 
deep learning techniques. A recent study (Yang, Rangarajan, & Ranka, 2018) utilized multiple 
methods to generate visual explanations for AD classification despite relatively low classification 
performance (0.863 AUROC, 76.6% accuracy) on a small dataset consisting of 47 AD and 56 CN 
subjects. Ablation tests constitute one classic method for probing a predictive problem to assess 
the usefulness of various features by dropping the features from consideration. Our study 
complements the saliency map based analyses with ablation tests to assess the predictiveness of 
each region to AD. 
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 Most previous studies on AD classification with CNNs (Hosseini-Asl et al., 2018; S. 
Korolev et al., 2017) exploit the (single) baseline scan for each subject and train their models to 
predict the cross-sectional diagnosis labels (assessed at scan time). (Payan & Montana, 2015) 
utilizes multiple scans but did not explicitly address potential data leakage and disease progression 
problems. (Wegmayr et al., 2018) explicitly addresses the data leakage problem (they refer to it as 
subject duplication), ensuring non-overlapping subjects in training and test sets, however, the 
disease progression is not explicitly discussed while stating several scans of an individual subject 
typically have the same disease label, which could be potentially problematic especially for their 
three-way classification task including MCI. Another difference from this previous study is that 
we opted to only include multiple scans from different sessions rather than within-session duplicate 
scans to leverage the data richness vs. data redundancy. 
 
3.1.1.4 Contributions 
In this study, we particularly focus on two specific aspects: (i) incorporating longitudinal scans as 
an unconventional data source, and (ii) a thorough investigation aimed at localizing the most 
predictive regions. Generally, data augmentation helps to prevent models from overfitting. In 
typical photographic images, such transformations include random crops, translations, rotations, 
etc. (Krizhevsky et al., 2012). Here, instead, we enrich the data by including images captured from 
the same patient across multiple visits. Inclusion of longitudinal scans raises two important issues: 
the data leakage problem and the disease progression problem. Data leakage occurs when the 
training and test sets contain the different scans from the same subject, the model might make the 
prediction by memorizing and retrieving the label from the same person and is likely to result in 
over-optimistic performance. This issue is dealt with easily by ensuring that the partition into 
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train/validation/test splits takes place at the level of the individual patients instead of at the level 
of the scan. The disease progression problem relates to the fact that the disease status of subjects 
might change in follow-ups, and the cross-sectional diagnosis labels for a certain scan might be 
different from the baseline label, this is especially important in prodromal disease status, e.g. MCI 
in AD pathology. 
 Our model achieved high classification performance in AD classification in a large dataset 
consisting of 2817 scans/sessions from CN subjects and 1874 scans/sessions from AD subjects. 
Moreover, we found that by applying model trained on AD vs. CN classification to baseline scans 
of MCI subjects, we could accurately predict progression from MCI to AD. Furthermore, I studied 
the neuroanatomical underpinning in AD classification with a series of novel regional analyses 
following the regional vulnerability idea (Scott A. Small, 2014). The analyses pinpointed 
hippocampal formation as a most predictive driver for our deep learning-based AD diagnosis 
model, which further affirms the prominence of hippocampal formation in AD classification. I 
explored regional significance in a number of ways. In one approach, I generated a 3D saliency 
map post hoc without any changes to the model or input data, presenting the whole brain volume 
to the classifier and inferring regions that contribute most to the classification using a 3D class 
activation mapping (CAM) technique (Zhou, Khosla, Lapedriza, Oliva, & Torralba, 2016). 
Gradient-weighted CAM (grad-CAM) (Selvaraju et al., 2017) generalize the CAM to broader 
CNN families by flowing the gradients of the target label into the last convolutional layer. In this 
study, I utilized 3D grad-CAM to determine which specific 3D regions most indicate a prediction 
of AD. I also explored two “ablation”-based methods that explicitly focus on specific brain regions. 
The first method consists of training models to predict AD using 2D MRI slices (in each of the 
three coordinate planes), and evaluate the pattern of the capabilities of slices differentiating AD. 
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The second method, more informed of neuroanatomy, consists of masking specific regions using 
masks generated from a sub-population with segmentation, training on the masked regions, and 
comparing the classification accuracy. 
 The CAM method reveals a preponderance of activation overlap containing the left anterior 
hippocampal formation (HF). Evaluation on 2D MRI slices demonstrates the importance of slices 
covering the HF in the classification of AD using deep 2D CNN model. And evaluation on isolated 
brain lobes also demonstrates the importance of temporal lobe, which contains the HF. These 
findings have implications for both the interpretability of CNNs used in image-based disease 
diagnosis and also the prospective MRI acquisition protocols targeting AD diagnosis. Even for 
highly complex and nonlinear models, regionality and the underlying pathology revealed still 
manifests importance. 
 Importantly, it should be noted that our proposed 3D CNN model and regional analyses 





The dataset used in this study is from the Alzheimer’s Disease Neuroimaging Initiative5. The 
details about the MRI data acquisition can be found in ADNI website6. The T1-weighted structural 





MRI scans were pre-processed with the standard Mayo Clinic pipeline7. The AD diagnosis was 
based on clinical evaluations. The MRI and diagnosis data were queried and accessed at August 
2017. The diagnosis includes AD, MCI, and cognitively normal (CN). The dataset used to generate 
the regional masks includes 382 scans from unique elderly subjects in ADNI-2 and 1113 scans 
from unique young subjects in Human Connectome Project (HCP)8 (David C. Van Essen et al., 
2013). The subjects cover age 25-90, and clinical diagnosis of young normal control (N = 1113), 
elderly normal control (N = 120), MCI (N = 138) and AD (N = 124). 
 For the experiment of AD vs. CN classification, we sought to include as many MRI 
sessions as possible that correspond to AD or CN diagnosis at scan time. Specifically, I included 
the baseline and follow-up scans of patients diagnosed as AD at baseline, the baseline and follow-
up scans of subjects diagnosed as cognitively normal at baseline before the conversion to AD or 
MCI if ever happened, and the after-conversion follow-up scans of subjects who were CN or MCI 
at baseline but later progressed to AD. In total, I included 4691 scans (2817 CN, 1874 AD) from 
1189 subjects under these criteria. This experiment setup basically sets an upper limit to the amount 
of data for cross-sectional AD vs. CN classification in ADNI cohort. The inclusion of scans after 
conversion also helps enrich the samples around the “classification boundary” as will be more 
thoroughly discussed in the 3.1.2.3 “Inclusion of longitudinal scans” section. 
 I used 8/10 of the subjects as training set consisted of 3709 scans (2240 CN, 1469 AD) 
from 952 subjects, 1/10 as validation set consisted of 456 scans (279 CN, 177 AD) from 119 
subjects, and 1/10 as test set consisted of 526 scans (298 CN, 228 AD) from 118 subjects. As 





discussed in the Introduction section in this chapter, the training, validation and test sets split was 
partitioned at subject level through stratified random sampling on baseline diagnosis labels so that 
the groups have non-overlapping subjects and approximately even distribution of baseline 
diagnosis labels. The final model is selected as the one that has the highest validation accuracy (i.e. 
classification accuracy in validation set). 
 For the experiment of MCI progression prediction on baseline scans, I trained another 
model only using subjects whose baseline diagnosis are cognitively normal or AD to prevent data 
leakage. I included scans from 796 subjects under this criterion. Similarly, 2918 scans (1943 CN, 
975 AD) from 626 subjects were used as training set, 382 scans (251 CN, 131 AD) from 80 subjects 
were used as validation set, 325 scans 229 CN, 96 AD) from 80 subjects were used as test set. I 
used the same neural network training setup. I included 318 MCI stable subjects and 311 MCI 
progression subjects for MCI progression prediction. The MCI stable subject are those who 
remained MCI during a follow-up period of at least 3 years from the initial visit. The MCI 
progression subjects progressed to AD at follow-up visits, among which 256 subjects progressed 
to AD within 3 years. 
 We further evaluated our model on an independent AD dataset MIRIAD9 (Malone et al., 
2013). MIRIAD includes 455 MRI scans from 46 AD subjects, and 243 MRI scans from 23 
cognitively normal subjects. 




 We also derived AUROC using bilateral hippocampal volume normalized by intracranial 




Basic pre-processing steps include nonparametric nonuniform intensity normalization (N3) based 
bias field correction (Sled, Zijdenbos, & Evans, 1998), brain extraction using FreeSurfer (Ségonne 
et al., 2004), and 12 degree of freedom affine registration (using FSL FLIRT (Jenkinson, Bannister, 
Brady, & Smith, 2002) with normalized mutual information cost function) to the 1mm isotropic 
MNI152 brain template. The dimension of the 3D volume is 182 × 218 × 182 (LR×AP×SI). 
 Bias field correction is generally robust, fast, and based on physics models which act as a 
strong prior (Sled et al., 1998). There are brain extraction methods using deep learning techniques, 
but there is not one that is well-validated and widely-available. Skull-stripping using FreeSurfer 
provides consistently high-quality brain extraction. 
 The registration is to ensure same orientation and roughly same spatial correspondence of 
different images. Although there are techniques such as spatial transformer network (Jaderberg, 
Simonyan, & Zisserman, 2015) to learn transformation within the network, it would involve more 
parameters to learn and add burden to the data. All the brain extracted, affine-transformed images 
were checked by a well-trained reviewer with visual inspection. Scans having severe MRI artefacts, 




3.1.2.3 Inclusion of longitudinal data 
Commonly, computer vision practitioners synthetically augment their datasets, applying random 
transformations to existing training images. However, unlike natural images or certain kinds of 
medical image, where objects of interest might vary in location and rotational orientation, MRI 
images of brains are approximately at the same position through registration, with the brain regions 
roughly aligned. Thus, in this setting, learning rotational and translational invariances is not well 
motivated. 
 There is another form of data augmentation or more precisely “data source” specific to 
medical imaging applications. For longitudinal studies, test-retest studies and just ordinary studies, 
there might be multiple scans per subject. By including time as a factor in subject identification, 
we can increase the amount of data. In a sense, by including these data sources, we are seeking 
natural forms of data augmentation. The corresponding “transformations” would be normal aging, 
disease progression or both (longitudinal scans with a significant interval between scans), subject 
re-positioning (scans acquired at different sessions and within a short period of time) and subject 
motion (scans acquired at the same session). The variability present in the scans or the data 
coverage in the data space decreases in this order. The illustration of the general idea is shown in 
Figure 3-1. As discussed in the Introduction section in this chapter about disease progression, 
special attention is required for the first kind, where the different time points of the same individual 
might be at different health or disease stages. Moreover, those scans, lying on the verge of different 
diagnosis, constitute informative cases for the classification. 
 In this study, I opted for using scans from different sessions, which already provides a 
significant increase in the amount of data: from 796 baseline scans to 4691 scans. And scans from 




Figure 3-1. Illustration of data augmentation or inclusion of longitudinal scans specific to 
longitudinal neuroimaging studies for machine learning models. The whole plane is a 
simplified representation of the data space. Each large circle indicates one individual subject, each 
small circle indicates one MRI session. Each coronal slice of MRI scan represents one scan. The 
objective of the deep learning algorithm is to find the “boundary” (dashed line) that best 
differentiates cognitively normal subjects and AD patients. Enriching our data by using 
longitudinal scans from subjects helps to increase the data coverage from the small circle to the 
large circle. 
 
3.1.2.4 Convolutional neural network 
I used a general CNN architecture similar to the VGG classification architecture (Simonyan & 
Zisserman, 2014) with multiple interleaved convolutional blocks and max pooling layers and 
increasing number of features along the depth. The main differences include having just one fully-
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connected layer to significantly reduce the number of parameters and replacing 2D operations with 
3D operations. For convolutional layers, I used a convolutional kernel size of 3 × 3 × 3, a batch 
size of five, rectified linear unit (ReLU) as the activation functions. The output from the last 
convolutional layer is flattened and fed into a fully-connected (FC) layer with sigmoid as the 
activation. I used batch normalization (BN) before the activation function.  
 
Figure 3-2. The convolution neural network architecture for AD classification. The inputs are 
3D brain volumes. Each cubic represents one 3D feature map, the size reflects the spatial 
dimension of the feature map, and the number reflects the number of feature maps (channel 
dimension). The blue arrows are 3D convolutional operations, the green arrow represents batch 
normalization (BN) followed by rectified linear unit (ReLU), the yellow arrow denotes the max 
pooling operation. The basic unit enclosed in the bracket is repeated N = 5 times with increasing 
number of features and decreasing spatial dimension. The final convolutional output is flattened 
and fed into one fully-connected (FC) layer with sigmoid activation function (red arrow), 
generating the final AD score, a value between 0 and 1 reflecting the likelihood of diagnosis. 
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 The algorithm was optimized using Adam method with cross-entropy loss function. The 
initial learning rate was tuned in the range from 1e-4 to 1e-6 including [1e-4, 5e-5, 2e-5, 1e-5, 5e-
6, 2e-6, 1e-6] and was set at 2e-5. The algorithm was implemented using Keras and TensorFlow. 
As early stopping criteria, I set the patience parameter on validation accuracy to 10 epochs. I 
included weight l2 regularization to prevent overfitting with a factor of 1.0. An illustration of the 
framework is shown in Figure 3-2. In this study, I used five (N in Figure 3-2) stages. The feature 
dimension of the first layer is 16 and increases by a factor of two in each subsequent stage. 
 
3.1.2.5 Application to MCI progression prediction 
The classification was trained on AD vs. CN, which presents the largest neuroanatomical contrast 
in the AD spectrum. Whether the model learned using the two ends of the spectrum could inform 
the differentiation of patients in the middle of the spectrum is critical. The model was directly 
applied on the baseline scans of patients diagnosed with MCI since MCI patients are not part of 
the training dataset of the model. AUROC was used to evaluate the prediction performance. 
 
3.1.2.6 Class activation map 
Class activation map (CAM) original proposed by (Zhou et al., 2016), extended and generalized 
in gradient-weighted CAM (grad-CAM) (Selvaraju et al., 2017), has been used in medical image 
analysis field to inform the “attention” of the 2D classification (Feng, Yang, Laine, & Angelini, 
2017). In this study, I generated 3D grad-CAMs to visualize the predictive contribution of brain 
regions to the AD classification task. Importantly, since the map can be generated individually, it 
can be used as an individual neuroanatomical validity report without sacrificing the prediction 
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power of whole-brain based prediction model. I generated the average class activation map for all 
AD patients to demonstrate the average “attention” of the algorithm. 
 For class activation mapping, the classification score can be formulated as follows: 
 
where σ is softmax function,𝑤𝑖  is the learned weight for each feature map 𝐴𝑖 , and 𝑎𝑖 =
∑ 𝐴𝑖(𝑥, 𝑦)(𝑥,𝑦) . Following this formulation, the class activation map can be expressed as follows: 
   
 
3.1.2.7 MRI 2D slice based classification 
Besides the post hoc saliency map based class activation map method, I also propose ablation 
analyses focusing on part of the input data. I tested the classification using 2D CNN with the input 
being three consecutive slices as three channels. This design takes the inter-subject alignment 
precision into consideration (i.e. not extracting just one slice) and also ensuring relative similarity 
among different channels (i.e. not extracting five slices). The network architecture is the same as 
the 3D CNN architecture described above except that the 3D operations are all replaced with the 
corresponding 2D operations. The classification performance on different groups of 2D slices as 
the indication of predictive importance were reported. 
 










3.1.2.8 Brain lobe based classification 
Slice-based regional analysis method investigates the predictive regions of the classification from 
imaging perspective, as the coordinate planes are imaging planes. But each slice still represents a 
mixture of multiple regions located at a certain spatial level. It is more appealing to generate 
neuroanatomically meaningful regions and perform classification focusing on these regions 
separately. A probabilistic spatial distribution of different regions was derived from the affinely 
co-registered FreeSurfer segmentations (Bruce Fischl et al., 2002; B. Fischl et al., 2004) from 
1,495 scans as detailed in the 3.1.2.1 Data section. An occurrence probability of 0.5% was used as 
the threshold for the lobe mask generation. The definition of lobes in FreeSurfer segmentation 
nomenclature is referenced in FreeSurfer10, with the exception that temporal lobe also includes 
medial temporal lobe structures (hippocampus, amygdala). I focused on the lobe-level ablation 
study because the brain lobes are functionally and structurally distinct units, and also because finer 





3.1.3.1 AD classification 
The classification performance of AD vs. CN task is shown in Figure 3-3. I evaluated the model 
both on unique MRI sessions and the first scans of unique subjects. Our model achieves 0.980 




AUROC and 93.3% accuracy at scan level, and 0.990 AUROC and 96.6% accuracy at subject 
level. The AUROC evaluated using hippocampal volume is 0.916. 
 For the independent MIRIAD dataset, the ROC curves can be found in Figure 3-4, showing 
similar performance: 0.980 AUROC and 92.7% accuracy at subject level and 0.987 AUROC and 
94.4% accuracy at scan level. The AUROC evaluated using hippocampal volume is 0.895. 
 The high overall classification accuracy of our model lays a solid foundation for our 
subsequent results investigating regional attribution. The model training process with only baseline 
scans under identical training settings stuck at uniform classification label. 
 
Figure 3-3. ROC curves for AD classification on the test set at (Left) scan level and (Right) 




Figure 3-4. ROC curves for MRI-based AD classification in an independent dataset MIRIAD 
at the (Left) scan-level and (Right) subject-level. The AUROCs are annotated in the figures. 
 
3.1.3.2 Application to MCI progression prediction 
Remarkably, we found that the classifier trained exclusively on AD and CN patients can also be 
used post hoc to differentiate among those MCI patients who will and will not progress in the near 
term to AD. The ADNI dataset contains MCI patients whose subsequent progression or not to AD 
has been noted retroactively. Ideally, we might train a model exclusively on MCI patients whose 
subsequent progression status has been observed, directly learning to distinguish AD’s prodromal 
stage from other causes of MCI. However, the subset of MCI patients (around 600) is not sufficient 




Figure 3-5. ROC curve for MRI-based MCI progression prediction, with the AUROC 
annotated in the figure. 
 To determine the usefulness of our AD vs. CN classifier for recognizing those MCI cases 
that will progress to AD, the imaging data of MCI patients was fed through an AD vs. CN binary 
classifier, interpreting a higher probability of AD as more likely to progress to AD and a higher 
probability of CN as less likely to progress. For this experiment, we trained the AD vs. CN model 
using only baseline scans from subjects diagnosed as either AD or CN at baseline (as detailed in 
the 3.1.2.1 Data section) achieving an AUROC of 0.973 on i.i.d. holdout data. Then we fed our 
evaluation set of MCI patients through the classifier, achieving an AUROC of 0.787 (0.808 when 
including only MCI patients who progressed or stayed stable within 3 years), matching state-of-
the-art performance while using structural MRI data only (I. O. Korolev, Symonds, & Bozoki, 
2016). In Figure 3-5, we plot the performance of our classifier as applied post hoc to the task of 
predicting MCI progression. Note that this evaluation procedure applies the CNN out-of-sample 
to a subset of patients that are not represented in the training set. In general, machine learning are 
liable to break under distribution shift and thus our performance, despite matching the previous 
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state-of-the-art, might still have margin from the ceiling of what we might achieve given adequate 
data. This result supports the concept that the neuroanatomical pattern of MCI partially lies on the 
normal-to-AD continuum. 
 
3.1.3.3 Regionality analyses 
3.1.3.3.1 Class activation map 
The average class activation map for all AD patients overlaid on the MNI152 brain template was 
illustrated in Figure 3-6. A 3D rendering of the iso-surface of the AD class activation map is shown 
in Figure 3-7. We can see from the figures that the average AD/class activation map shows large 
“activation” in hippocampal formation, suggesting the importance of hippocampal formation in 
differentiating AD in our 3D deep CNN model. Since it is not as straightforward to show scattered 
activations in the figure, I generated regional class activation map values to show the extent of less 
focalized regions both for AD (Figure 3-8) and MCI (Figure 3-9). 
 
Figure 3-6. Average class activation map of AD classification overlaid on the MNI152 MRI 





Figure 3-7. 3D rendering of the AD class activation map. The iso-surface is at the level of 0.8. 
 
Figure 3-8. The average regional AD class activation values. The left MTL regions indicated 
with red color show prominence, not as prominent, the right MTL regions are also among the first 




Figure 3-9. The average regional MCI class activation values. Similar to the AD class 
activation map, the left MTL regions indicated with red color show prominence. However, the 
activation map is overall more scattered with the highest regions only reaching 0.5 level. Besides 
the left MTL blob, there are two additional prominent blobs in parietal and frontal lobes. 
3.1.3.3.2 MRI 2D slice-based classification 
We also explored a slice-based classification scheme to determine which slices are most predictive 
of AD (Figure 3-10), running the analyses three times, using 2D slices along the sagittal, coronal, 
and axial dimensions. Along each dimension, those slices achieving highest classification 




Figure 3-10. MRI 2D slice based AD classification. (Top row) The classification AUROC on 
the test set using 2D slices at different locations, the red lines indicate the location with highest 
AUROC. (Bottom row) The illustration of slices at the red lines in the top row from the MNI152 
template and the corresponding regional segmentation (the colors follow the FreeSurfer color 
lookup table: yellow - hippocampus, red - entorhinal cortex). 
3.1.3.3.3 Brain lobe based classification 
In addition to the evidence for the importance of hippocampal formation provided by our 2D slice-
based analysis, I also explored a more anatomically-informed method. Here, I explicitly train the 
model on different lobes and cerebellum, masking the others with the masks derived from a 
population probabilistic map. As shown in Table 3-1, the model trained on the temporal lobe, 
which includes hippocampal formation, achieves the highest AUROC of 0.944 and accuracy of 
88%. The next most predictive lobe is the frontal lobe (0.899 AUROC and 83% accuracy). 
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Table 3-1. AD classification performance achieved using individual lobes and cerebellum. 
Lobes Frontal Parietal Temporal Occipital Cerebellum Whole-brain 
AUROC 0.899 0.857 0.944 0.836 0.687 0.980 
Accuracy 83% 78% 88% 74% 67% 93% 
 
3.1.4 Discussion 
3.1.4.1 AD staging and dysfunction spread 
In Braak staging of AD (Braak & Braak, 1991), the dysfunction represented by neurofibrillary 
tangles starts from transentorhinal cortex (TEC) (stage I, II) to limbic regions (stages III and IV) 
and spreads to neocortical at stage V and VI. Additionally, a previous fMRI study has suggested 
cortical spread of dysfunction originating from lateral entorhinal cortex (LEC) (Khan et al., 2014). 
While our findings cannot by themselves establish pathophysiological primacy, they provide 
evidence of structural prominence for the hippocampal formation. These results support the theory 
that the area circumscribing the anterior hippocampal formation is one most affected structural 
region in AD (Killiany et al., 2002). 
 
3.1.4.2 Localization 
Our regional analyses showed that multiple approaches of localization, including class activation 
maps, slice and brain lobe level ablation experiments, suggest that the hippocampal formation is 
the region most predictive of AD. While the interpretation of traditional statistical parametric 
mappings generated from mass-univariate methods (Friston et al., 1994) may be more familiar in 
the medical imaging community, CNNs are often considered harder to interpret, owing to complex 
nonlinear patterns and interactions among voxels that these models capture. As a result, they are 
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often considered to be black-boxes, useful for pattern recognition and classification but less 
amenable to interpretation. The trade-offs between separability and interpretability have already 
been discussed in multivariate based analysis, and is becoming more obvious with the more 
complex architecture of deep neural networks. 
 However, this work highlights that through a combination of evidence produced by both 
heuristic saliency-map-based interpretations and rigorous slice and lobe level ablation studies, 
CNNs can be used not only for predictions but also to provide insights with likely neurobiological 
underpinnings. This work presents an important case study bridging the separability and 
interpretability. 
 While the hippocampal region does appear especially predictive of AD, we emphasize that 
all regions offer predictive values. Thus, in practice, for building tools to aid in the diagnosis of 
AD, and for predicting progression to AD among the MCI population, we recommend training 
models that act upon whole brain volumes. Indeed, our models acting upon whole brain volumes 
achieved the best AUC as compared to those acting upon any single slice or lobe. 
 This work relates to the multiple pathologies observations in AD (Power et al., 2018), and 
argues the focal neuroanatomical atrophy in hippocampal formation potentially unifies 
Alzheimer’s disease in the presence of multiple pathologies. Since there is not a quantitative and 
meaningful local measure of structural information from structural MRI to do simple whole-brain 
voxel-based analysis or linear multivariate analysis, we deem our current approach best suited for 




3.1.4.3 Prodromal disease classification using progressed cases 
This study suggests the value of training a model on anchored disease or non-disease states with 
the utility of applying that model on classifying prodromal disease states; in this case MCI subjects 
who progress to AD. Many neurological and psychiatric diseases have known prodromal states, 
reflecting either mitigated or absent symptoms, or biomarkers that do not meet criteria for disease. 
These individuals are considered in a “high-risk” category, whereby only future classification (or 
failure to convert within a time frame) determines whether an individual had prodromal disease or 
another distinct illness. Neuroimaging may be sparse for these groups (due to difficulty in 
recruiting, for example, especially for rarer diseases) and such neuroimaging findings may be too 
subtle for traditional volumetric or segmentation based single subject analysis. By using a deep 
learning network enriched with data from confirmed disease states and controls, such a network 
may have value in screening for disease in broad populations, where the advanced disease has a 
distinct structural imaging signature which can easily and quickly be applied to high-risk states. 
 
3.1.4.4 Applicability and Practicality 
One advantage of our approach compared to many other neuroimaging methods is the range of 
MRI images onto which this technique can be feasibly applied. Given that the only pre-processing 
steps required are brain extraction and registration, this technique could provide a classification in 
a few minutes for any comparable T1-weighted image. Furthermore, the model can be retrained 
with more data, including data with noise or potential artefact that might prevent other standard 
imaging analytic techniques. It is possible that the retrained model could account for such artefacts 
better than traditional analytic streams. 
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 The localization observations also have potential practical implications for acquisition. 
Acquisition targeting a focal field of view can facilitate diagnosis of specific disorders in the event 
of any time or condition constraints. And, it is important to note that the proposed method is able 
to generate a summary score for the structural AD-like pattern with very low computational cost 
at inference comparing with most of the current segmentation-based models. This is very critical 
in timely diagnosis and evaluation. Additionally, the computational requirement for a study this 
size was modest, both in cost and time, and easily adaptable into a pipeline. 
 
3.1.4.5 Limitations 
This study has several important limitations. Firstly, each MRI, even when multiple scans from 
the same subject are available, are treated individually. Thus our dataset contains multiple scans 
from the same individual and thus those individuals that have received many scans are over-
represented relative to those who undergo fewer scans in model training and evaluation. 
Distribution of the number of scans per subject can be found in Figure 3-11. In order to ensure that 
the multiple scans per person do not introduce any target leaks into our learning problem, we take 
care to construct our training, validation and testing splits on a per-individual (vs. per-scan) basis, 
isolating each subject to only one split. Still it is worth noting that the most heavily scanned 
individuals contribute more heavily to the learned model and to the evaluation. Conceivably, if 
one were interested in assessing the accuracy of predictions on a per-individual level, one might 




Figure 3-11. MRI sessions per subject: (left) scans of cognitively normal subjects, (right) 
scans of AD subjects. 
 Additionally, we note that our labels used in both training and evaluation are not ground 
truth per se as they are based on physicians’ assessments via clinical criteria in vivo while true 
diagnosis can only be confirmed at present through neuropathology, requiring post-mortem brain 
biopsy. Although ante- and post-mortem concordance is generally found to be high, the availability 
of ground truth labels might help improve diagnosis (Beach, Monsell, Phillips, & Kukull, 2012). 
 The current study aims to make predictions about the diagnosis at the time of scan, which 
permits different diagnosis labels of multiple scans of the same subjects. Future studies with the 
goal of predicting longitudinal progression may define the class labels based on the most recent 
diagnosis label and the follow-ups. 
 The probabilistic spatial distribution used in brain lobe based classification experiment can 
be further optimized to be more reflective of general population but is not the aim and beyond the 




3.1.4.6 Implications for the present AD biomarker system 
The current AD biomarker system mainly consists of amyloid, tau, and neurodegeneration (A/T/N) 
(Clifford R. Jack et al., 2016), and some emerging biomarkers (Scott A. Small, Simoes-Spassov, 
Mayeux, & Petsko, 2017), although studies have shown the limitation of the current classification 
system reaching enough consistency to be used in the clinical setting (Illán-Gala et al., 2018). 
Machine learning could potentially bridging different biomarkers. In structural MRI, we can 
develop multiple models that provide structural correlates of different categories of biomarker 
including tau, Aβ. In this way, we are generating tau-informed or Aβ-informed neurodegenerative 
biomarkers. Similarly, we could derive Aβ measures from tau-PET, this way generating Aβ-
informed tau biomarkers. When used for prodromal state detection, one way to interpret the 
measures is to extract and limit information relevant to the characteristics of an earlier phase. A 
preliminary analysis of generating CSF biomarker correlates from structural MRI was included in 
the appendix, the estimation performance still has room to improve but demonstrate the proof-of-
concept. 
 This also has further practical implications. We can transfer the rich biomarker information 
from large-scale initiatives such as ADNI to other small-scale applications. 
 
3.1.4.7 Future work 
Our framework is sufficiently general that it can be easily extended to other diseases such as 
schizophrenia, Parkinson’s disease (PD), etc. and to other MRI contrasts such as CBV, CBF or 
even to other imaging modalities such as PET, SPECT. One promising direction is a large-scale 
CBV study enabled by the recently proposed retrospective CBV technique (Feng, Hamberger, et 
al., 2018). Moreover, our ability to learn good representations for AD prediction could be brought 
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to bear on other problems that might be supported only by smaller datasets. Following a number 
of successes in deep learning applications ranging from computer vision to natural language 
processing, we might employ transfer learning, fine-tuning the representations from our AD 
predictor, together with other sources of information such as age, gender, functional imaging 
measures, neuropsychological measures, CSF biomarkers, etc. to new tasks. 
 
3.1.4.8 Conclusion 
In this study, we proposed an AD diagnosis framework based on deep 3D CNN model using 
structural MRI, empowered with the inclusion of longitudinal scans. The proposed framework 
demonstrates high classification performance in AD vs. CN. In addition, we demonstrated high 
accuracy in MCI progression prediction applying the model trained on AD vs. CN classification 
to the MCI subgroup. Furthermore, through class activation map and rigorous slice and lobe-level 
ablation analyses, we pinpointed hippocampal formation as the most predictive regions for AD 
classification, affirming the prominence of hippocampal formation in AD diagnosis, and 
demonstrating the importance of regionality even in highly complicated deep neural network 
models. And importantly, the proposed classification and regional analyses methods constitute a 




3.2 Comparative studies to other AD pathology measures in prodromal AD 
detection 
3.2.1 Introduction 
Alzheimer’s disease (AD) progresses through a prodromal stage that presents clinically as mild 
cognitive impairment (MCI), before progressing to dementia (Petersen et al., 1999). MCI’s 
prevalence ranges between 7% to 25% of the aging population, depending on age-group and other 
demographics (Sachdev et al., 2015; Vos et al., 2015; Ward, Arrighi, Michels, & Cedarbaum, 
2012), but only a portion of MCI patients have prodromal AD. With increased awareness and 
concern over AD, a growing number of MCI patients are presenting to health care providers, 
wanting to know whether their symptoms are caused by early stages of the AD, and if so how 
quickly they will progress to dementia.  
 Biomarkers hold promise in aiding the clinical evaluation of MCI, and biomarkers 
currently exist for the three core neuropathologies of AD—amyloid pathology, tau pathology, and 
neurodegeneration (Clifford R. Jack & Holtzman, 2013; Olsson et al., 2016). The first two can be 
estimated from CSF levels of Aβ and tau, or by indirect visualization using PET-sensitive 
radioligands. Neurodegeneration, a term currently used to encompass neuronal or synaptic loss 
(Khan et al., 2014), can be estimated from PET-based measures of parietal cortex metabolism, or 
MRI-based measurements that reflect the structural integrity of the hippocampal formation.  
 Large scale studies in patients with AD dementia are beginning to establish reliable 
diagnostic cutoffs from their parametric distributions. Applying these dementia cutoffs to 
dichotomize MCI patients into those who are biomarker “positive” or “negative” is one approach 
to determine which biomarker category (amyloid, tau, neurodegeneration) using which biomarker 
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technology (biofluidics or neuroimaging) best classifies patients with prodromal AD. Survival 
analyses can then be used to determine which biomarkers best predict progression to AD dementia. 
This approach, however, is potentially problematic since the cutoffs are derived from patients in 
the dementia stage of disease (L. M. Shaw et al., 2009). Biomarkers shift over the chronically 
progressive course of the disease, particularly dynamic during its early stages (Anne M. Fagan et 
al., 2014) so that this design is prone to both type I and type II errors.  
 An alternative approach that can sidestep this problem is to rely on conversion to dementia 
information to retroactively dichotomize MCI patients into those with and without prodromal AD 
at baseline, and use receiver operating analyses to determine which biomarker best classifies 
disease. The challenge with this design is that, based on current estimates, approximately 5 years 
of clinical follow-up is needed in order to allot sufficient time for the majority of prodromal AD 
patients to clinically manifest (Mitchell & Shiri-Feshki, 2009; Visser, Kester, Jolles, & Verhey, 
2006). Thanks to the ADNI, which has been acquiring biomarker data in MCI patients since 2005, 
this design is now possible. Here, we apply this second experimental design to ADNI data. Based 
on the understanding of disease pathophysiology and previous studies (Vemuri et al., 2009), we 
hypothesize that biomarkers of amyloid and tau pathology would outperform other biomarkers in 
classifying prodromal AD, but that biomarkers of neurodegeneration might outperform others in 
predicting time to progression.  
“Deep learning” is a subset of machine learning that has proven successful in categorical 
image classification (LeCun et al., 2015), and when applied to MRI might prove useful in AD 
detection (Feng, Yang, Lipton, Small, & Provenzano, 2018). We have recently developed a deep 
learning algorithm that is distinguished by two assumptions: that a classifier based on individual 
voxels would be superior over one based on anatomical parcellation; and, that given the complex 
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three-dimensional organization of the brain, a classifier based on 3D information would be 
superior over one based on 2D information. We have used this algorithm to derive from 
conventional MRIs individual “deep learning MRI scores” (DLMRI scores), and have found that 
it classifies AD with high accuracy (Feng, Yang, et al., 2018). Remarkably, the DLMRI scores are 
dominated by differences in the medial temporal lobe, which contains the entorhinal cortex and 
hippocampus. We hypothesize that, compared to other MRI-based measures of the entorhinal 
cortex or hippocampus, DLMRI scores will improve MRI’s clinical utility.  
  
3.2.2 Methods 
3.2.2.1 ADNI cohort 
Five subsets of subjects from ADNI cohort were tested in this study: 1) ADNI MCI cohort with 
baseline structural MRI and in vivo CSF biomarker (N = 384); 2) ADNI MCI cohort with baseline 
structural MRI, in vivo CSF biomarker, FDG-PET and amyloid-PET (AV45-PET) measures (N = 
248); 3) ADNI MCI longitudinal cohort with at least one follow-up measure of in vivo CSF 
biomarker and structural MRI from the same visit in addition to the baseline structural MRI and 
in vivo CSF biomarker (N = 238); 4) ADNI cohort with antemortem MRI and postmortem 
neuropathology (N = 44); 5) ADNI cohort with tau-PET (AV1451-PET) (N = 296). The detailed 
criteria in each subset are introduced in the following sections. A diagram with subject inclusion 





Figure 3-12. Participant selection flow-chart. 
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3.2.2.1.1 ADNI MCI cohort with in vivo CSF biomarker 
Among all MCI patients with follow-up, we further confined our cohort by constraining the MCI 
stable criteria. The raw distributions of the follow-up lengths in the MCI-stable group, and the 
conversion time of MCI-progression group are shown in Figure A-4. We essentially excluded the 
left tail of the distribution in the MCI-stable group to decrease the proportion of potential 
prodromal AD incidence in the MCI-stable group.  
 We identified 384 baseline MCI subjects who have both MRI and in vivo CSF biomarkers 
at baseline (L. M. Shaw et al., 2009). Patients in MCI-stable group stayed stable in the follow-up 
visits and have a follow-up period of at least 4 years. The demographic information and the 
baseline measures compared are summarized in Figure 3-13 (and for more details, see Figure A-4). 
In this constrained cohort, MCI-progression takes up 53.4% of the whole population. Within this 
large cohort, we generated and compared with measures including: in vivo CSF biomarkers, 
morphometric measures, and neuropsychological measures.  
3.2.2.1.2 In vivo CSF biomarker 
CSF tau levels, reflective of neurofibrillary tangle, and CSF Aβ levels, reflective of amyloid 
pathology, were included in the analysis (Tapiola et al., 2009). Additionally, the tau/Aβ ratio, 
which has been shown to best capture AD (A. M. Fagan et al., 2007), was also included.  CSF was 
acquired at ADNI sites in accordance to the ADNI acquisition protocols and analyzed as 
previously described (L. M. Shaw et al., 2009).  The median values provided by ADNI were used. 
3.2.2.1.3 Morphometric measures 
We used FreeSurfer 6.0 (Bruce Fischl et al., 2002; B. Fischl et al., 2004) to segment the same set 
of scans and derive regional morphometric measures. Hippocampal (HC) volume, entorhinal 
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cortex (EC) volume, entorhinal cortex thickness were used as AD vulnerable structural measures. 
Hippocampal and entorhinal volume were normalized by the intra-cranial volume (ICV). 
 
Figure 3-13 . Distribution and demographics of study participants. Distribution frequencies of 
the patients with amnestic mild cognitive impairment (MCI) at baseline, who either remained 
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stable (MCI stable) or progressed to Alzheimer’s dementia (MCI progression), organized by latest 
follow-up years and conversion years. The dark blue bars indicate subjects included in the study. 
Demographic and baseline biomarker data are listed in the table for the MCI stable and MCI 
progression groups. 
3.2.2.1.4 Neuropsychological measures 
All participants have neuropsychological measures available. For neuropsychological batteries, 
we tested the MMSE (Mini-Mental State Examination) score and the RAVLT (Rey Auditory 
Verbal Learning Test) retention score. RAVLT retention measure equals the number of delayed 
recalled words divided by the number of words learned in trial 5 and has been found to be one of 
the most sensitive to AD (Chang et al., 2010). 
3.2.2.1.5 ADNI MCI cohort with PET measures 
To compare DLMRI score with FDG and amyloid-PET measures, we further confined the subset 
into subjects who also had received baseline FDG and AV45-PET. We identified N = 248 subjects 
in this subset, including 154 in MCI stable group and 94 in MCI progression group. We used the 
composite FDG and composite AV45 scores provided by ADNI for analyses (Jagust et al., 2015). 
The FDG composite measure is the average FDG uptake of angular, temporal, and posterior 
cingulate (Susan M. Landau et al., 2011). The AV45 composite measure is the average AV45 
SUVR (standard uptake value ratio) of the frontal, anterior cingulate, precuneus, and parietal 
cortex relative to the cerebellum (S. Landau & Jagust, 2015). 
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3.2.2.1.6 ADNI MCI longitudinal cohort 
To investigate the longitudinal association of DLMRI score with CSF biomarkers, among the 384 
subjects with baseline CSF biomarkers, we identified 238 subjects with at least one follow-up 
measure of CSF biomarkers and structural MRI from the same visit. 
3.2.2.1.7 ADNI cohort with neuropathology 
Among 64 subjects with brain autopsy data, we identified 44 and 29 subjects with an antemortem 
MRI scan within two and one years before death, respectively. The closer to autopsy the last MRI 
was acquired, the more consistency we would expect for the measures from the two different 
sources. We derived DLMRI scores on the last antemortem structural MRI scans in this cohort. 
We analyzed the association with neuropathological measures including the Braak stage for 
neurofibrillary tangles (Braak & Braak, 1991) and the Thal phase for amyloid plaques (Thal, Rüb, 
Orantes, & Braak, 2002). Additional neuropathological measures include density of neocortical 
neuritic plaques (CERAD score, Consortium to Establish a Registry for Alzheimer's Disease) 
(Mirra et al., 1991), and the Alzheimer's disease neuropathologic change (ADNC) score (Hyman 
et al., 2012). 
3.2.2.1.8 ADNI cohort with tau-PET 
ADNI began acquiring PET scan using the AV1451 radioligand, which binds neurofibrillary 
tangles (Marquié et al., 2015), in the late phase of ADNI2 and resumed in ADNI3. Due to the 
smaller number of subjects with available longitudinal data or follow-up, we performed cross-
sectional analyses on these subjects with tau-PET. We used the regional tau measures generated 




3.2.2.2 Deep learning derived MRI score 
The deep learning model is a 3D convolutional neural network (CNN) model, and was trained on 
the brain-extracted T1-weighted structural MRI scans from the ADNI cohort of AD and 
cognitively normal subjects (Feng, Yang, et al., 2018). The continuous output from the model is 
reflective of the progressive structural patterns of AD pathology. We refer to it as a deep learning 
derived MRI (DLMRI) score. All subsequent analyses were performed using DLMRI score. More 
information about the deep learning model development and validation can be found in section 3.1 
and in our previous paper (Feng, Yang, et al., 2018). 
 
3.2.2.3 Statistical analysis 
3.2.2.3.1 ROC analysis 
We performed receiver operating characteristic (ROC) analysis for MCI progression prediction. 
We analyzed the standardized residuals controlling for age, sex, and APOE ε4 frequency using 
linear regression. We used DeLong test (DeLong, DeLong, & Clarke-Pearson, 1988) to test for the 
significance of the differences in the AUROCs (area under the ROC curve) from different 
measures using pROC R package (Robin et al., 2011). 
3.2.2.3.2 Survival analysis 
Cox proportional hazards regression models were fit to examine the association between baseline 
measures and time to conversion to AD dementia from MCI, controlling for age, sex, and APOE 
ε4 frequency, using survival R package (Therneau & Grambsch, 2013). MCI-stable subjects are 
included in the model as censored data with the last visit as the censored point. The high-risk and 
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low-risk survival curves were generated with 75% percentile and 25% percentile of the observed 
measures, respectively. 
3.2.2.3.3 Longitudinal analysis 
The longitudinal association between DLMRI score and CSF biomarkers was studied by 
examining the deviation from baseline measurements for each participant over time. The changes 
in either CSF biomarker or DLMRI score of all follow-up visits from baseline were used to 
estimate the slope  of the change in tau (tau), Aβ (Aβ), and tau/Aβ ratio (tau/Aβ) versus the 
change in DLMRI score (DLMRI) for each participant using linear regression through the origin. 
Each participant was represented by the point based on the last follow-up visit’s DLMRIlast (x-
coordinate) and the fitted change DLMRIlast (y-coordinate) of the respective measure. The last 
follow-up visit was used to anchor the representation of the participant in order to reflect the full 
follow-up. A correlation analysis was performed across participants. A linear regression model 
was fit across participants and illustrated. A single-subject illustration is shown in Figure 3-14.  
 
Figure 3-14. An illustration of the longitudinal measure derivation for a sample participant. 
The follow-up change measures from baseline were illustrated in the blue circles with the 
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corresponding visits annotated. Based on the follow-up change measures, a linear fit with slope β 
passing through the origin was estimated and illustrated as a red line. The DLMRI score at last 
visit (ΔDLMRIlast, x-coordinate) and the corresponding fitted change (βΔDLMRIlast, y-
coordinate), indicated as the diamond in the figure, can be calculated for each participant regardless 
of frequency of follow-up. 
 And the longitudinal analysis pipeline with MMSE vs. DLMRI score as an example is 
shown in Figure 3-15. 
 
Figure 3-15. Longitudinal analysis pipeline with MMSE vs. DLMRI score as an example. 
(Left) The raw longitudinal data with each colored line indicating one subject and each dot 
representing one visit time-point; (Mid) The linear fit of each individual, each line segment starts 
from (0, 0) and ends at (DLMRIlast , DLMRIlast ); (Right) The linear fit of (DLMRIlast , 
DLMRIlast ) across subjects. 
3.2.2.3.4 Correlational analysis 
We performed partial correlation between baseline DLMRI score and in vivo CSF biomarkers, 
regional tau-PET measures, controlling for age, sex, and APOE ε4 frequency. As the Braak staging 
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of neurofibrillary tangles and the Thal phase of amyloid plagues are both rank ordinal measures, 
we correlated the DLMRI score with the neuropathological measures using Spearman correlation. 
 
3.2.3 Results 
3.2.3.1 Classifying prodromal Alzheimer’s disease 
The ROC analyses revealed that the DLMRI score outperformed all other morphometric, 
neuropsychological, and CSF biomarker based measures at classifying MCI-stable group and 
MCI-progression group, with a 0.788 AUROC. AUROC (DeLong Test p values) for other 
measurements are Aβ: 0.0702 (0.0141), tau 0.682 (0.0161), tau/Aβ 0.703 (0.0161), hippocampal 
volume 0.733 (0.0484), entorhinal cortex volume 0.648 (2.01E-6), entorhinal cortex thickness 




Figure 3-16. Classifying prodromal Alzheimer’s disease. By comparing the ‘MCI stable’ to the 
‘MCI progression’ groups, ROC curves show that the ‘deep learning MRI’ (DLMRI) scores were 
found superior in classifying prodromal Alzheimer’s disease (indicated in red). DLMRI scores 
outperformed (left panel) CSF measures of Aβ, tau, or tau/Aβ; MRI measures of hippocampal (HC) 
or entorhinal cortex (EC) volume or thickness; clinical measures using the modified mental status 
exam (MMSE), the retention of the Rey Auditory Verbal Learning Task (RAVLT) (left panel); 
and, in a smaller subset (right panel), PET measures of amyloid using the AV45 radioligand or 
metabolism using fluorodeoxyglucose (FDG). Specific area under the curve (AUROC) values for 
each measure, and statistical probability values for each comparison, are shown in the table on the 
bottom panel. 
 We observe from the ROC curves in Figure 3-16 that the ROC curve of DLMRI score has 
higher overall sensitivity and specificity compared to the other measures for almost all levels. The 
differences in AUROC are statistically significant as described above and shown in Figure 3-16.  
 In the subset of subjects with PET measures available, we show the DLMRI score achieves 
better classification performance (AUROC of 0.815) than the amyloid-PET composite score 
(0.751) and FDG-PET composite score (0.782), though the difference is not statistically significant 
(p = 0.154 and 0.330, respectively), as shown in Figure 3-16. 
 
3.2.3.2 Predicting progression to AD dementia 
Demonstrating superior performance at identifying prodromal AD, we further compared the 




Figure 3-17. Predicting progression to Alzheimer’s Dementia. Survival analyses were 
performed comparing the DLMRI scores to other measures, and example curves illustrate that the 
DLMRI score (left panel) outperformed the CSF measure of the tau/Aβ ratio (right panel). The 
high risk (indicated by red) and low risk (indicated by blue) curves were fitted from 75% and 25% 
percentile of the measures respectively. The shaded area indicates the 95% confidence interval. 
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The DLMRI scores outperformed CSF Aβ, tau, or tau/Aβ, HC volume, EC volume, EC thickness, 
MMSE, RAVLT retention, amyloid-PET measure, and is comparable to FDG-PET measure, as 
shown in the table on the bottom panel. 
 The patterns are similar to the classification results in the previous section. DLMRI score 
shows better prediction capability (|z| = 11.0, p = 4.35E-28) than structural morphometric measures 
(HC volume |z| = 8.80, p = 1.35E-18, EC volume |z| = 6.02, p = 1.75E-09, EC thickness |z| = 7.42, 
p = 1.21E-13) neuropsychological measures (MMSE |z| = 5.72, p = 1.07E-08, RAVLT retention 
|z| = 6.88, p = 6.12E-12), CSF biomarkers (Aβ |z| = 6.37, p = 1.87E-10, tau |z| = 5.70, p = 1.18E-
08, tau/Aβ |z| = 5.41, p = 6.29E-08), and amyloid-PET composite scores (DLMRI PET cohort |z| 
= 9.05, p = 1.40E-19, AV45 |z| = 7.12, p = 1.04E-12); and comparable to the predictive 
performance of FDG-PET (|z| = 9.11, p = 8.14E-20). We illustrate the survival curves of both high 
and low DLMRI scores and tau/Aβ ratios in Figure 3-17, at 75% and 25% percentile of the baseline 
measures. 
 
3.2.3.3 Correlations with AD pathology 
Besides comparative studies with other measures in the prodromal AD classification and time to 
conversion prediction, we also studied the association of DLMRI score with reported AD 
pathology measures. It was important to determine whether the DLMRI score is linked to amyloid 
or tau pathology. Cross-sectionally, DLMRI score is significantly correlated with both Aβ level (r 
= -0.190, p = 1.86E-4), tau level (r = 0.225, p = 9.00E-6), and the tau/Aβ ratio (r = 0.209, p = 
3.90E-5), as also visualized in Figure A-5. The correlation with tau is marginally stronger than Aβ. 
Longitudinally, as shown in Figure 3-18, the DLMRI change is significantly associated with the 
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longitudinal change in tau levels (r = -0.205, p = 1.50E-3) and tau/Aβ ratio (r = -0.208, p = 1.26E-
3), but not with Aβ (r = -8.18E-3, p = 0.900). 
 And we further studied the association with the neuropathological measures, which are the 
most definitive way of characterizing AD, though with various time lag from the clinical visits in 
the lifetime. We show DLMRI score is more associated with Braak staging of neurofibrillary 
tangles than the Thal phase of amyloid plagues, as shown in Figure 3-18 and also visualized in in 
Figure A-6. 
 
Figure 3-18. The “deep learning MRI” score correlates with tau pathology. The scatter plots 
illustrate the relationship between changes over time in the DLMRI scores vs. changes in Aβ (left 
panel), changes in tau (middle panel) and changes in tau/Aβ (right panel). Each data point indicates 
one participant’s change of last DLMRI score from baseline (DLMRIlast), plotted against their 
change in biomarkers measures. The black solid lines are the linear fits across participants, 
showing that changes in the DLMRI score is most strongly correlated with changes in tau over 
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time. The table on the bottom panel lists the correlations between antemortem DLMRI scores to 
postmortem-derived Braak stage of neurofibrillary tangles and the Thal phase of amyloid plaques, 
with an MRI-autopsy interval of either 1 year or 2 years, showing that DLMRI scores are most 
strongly correlated with tau pathology.  
 Overall, we demonstrate DLMRI score strongly linked to global levels of both ante- and 
postmortem tau measurements. Thus, we further analyzed the regionality of the link with tau levels 
by looking into a tau-PET dataset, and show strongest correlations in MTL, particularly entorhinal 
cortex (r = 0.449, p = 1.66E-15). The full list of analysis results can be found in Table 3-2 for 
cortical regions and Table 3-3 for subcortical regions. 
Table 3-2. Partial-correlation statistics between cortical regional tau-PET measures and 
DLMRI score. The partial correlations control for age, gender, and APOE ε4 frequency. The 
regions are sorted in the order of correlation coefficients. 
cortical regions corr p-value 
 
cortical regions (cont.) corr p-value 
entorhinal 0.449 1.66E-15 
 
insula 0.347 1.79E-09 
inferiortemporal 0.440 7.45E-15 
 
lateralorbitofrontal 0.346 2.04E-09 
fusiform 0.428 4.16E-14 
 
precentral 0.337 5.41E-09 
temporalpole 0.427 5.16E-14 
 
medialorbitofrontal 0.324 2.39E-08 
parahippocampal 0.422 1.01E-13 
 
lateraloccipital 0.321 3.06E-08 
middletemporal 0.420 1.49E-13 
 
rostralmiddlefrontal 0.318 4.25E-08 
inferiorparietal 0.416 2.63E-13 
 
lingual 0.317 4.65E-08 
precuneus 0.416 2.66E-13 
 
cuneus 0.317 4.79E-08 
isthmuscingulate 0.416 2.77E-13 
 
parstriangularis 0.307 1.30E-07 
bankssts 0.415 3.03E-13 
 
paracentral 0.296 3.83E-07 
caudalmiddlefrontal 0.410 6.01E-13 
 
pericalcarine 0.293 4.89E-07 
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superiorparietal 0.389 1.06E-11 
 
parsorbitalis 0.291 5.83E-07 
posteriorcingulate 0.388 1.17E-11 
 
caudalanteriorcingulate 0.277 2.06E-06 
superiorfrontal 0.380 3.48E-11 
 
postcentral 0.271 3.63E-06 
superiortemporal 0.379 3.79E-11 
 
rostralanteriorcingulate 0.270 3.75E-06 
supramarginal 0.377 5.33E-11 
 
frontalpole 0.222 1.57E-04 
parsopercularis 0.351 1.19E-09 
 
transversetemporal 0.193 1.09E-03 
 
Table 3-3. Partial-correlation statistics between subcortical regional tau-PET measures and 
DLMRI score. The partial correlations control for age, gender, and APOE ε4 frequency. The 
regions are sorted in the order of correlation coefficients. 
Subcortical regions corr-coef p-value 
amygdala 0.454 7.82E-16 
putamen 0.336 6.37E-09 
hippocampus 0.272 3.34E-06 
pallidum 0.270 4.03E-06 
ventral DC 0.121 0.0420 
caudate 0.0923 0.121 
thalamus-proper 0.0889 0.135 
 
3.2.4 Discussion 
Supporting one hypothesis of this study, we find that DLMRI scores outperformed other MRI-
based measures in both classifying prodromal AD and in predicting progression to dementia. 
While strongly influenced by changes in the entorhinal cortex and hippocampus, the DLMRI 
scores are distinguished from other MRI-based measures by incorporating the entire brain in its 
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classification, agnostic of tissue type, volume or other pre-processing steps, likely accounting for 
its superior performance. Additionally, compared to measures of volume or thickness, the DLMRI 
scores are based on signal variability within individual voxels, and so is predicted to be more 
sensitive to synaptic loss, an earlier step in the neurodegenerative process (Khan et al., 2014).  
 Refuting another hypothesis, we found that DLMRI scores performed at least as well and 
typically outperformed biomarkers of amyloid and tau pathology in classifying prodromal AD. We 
do not consider this unexpected finding a challenge to the primacy of amyloid and tau pathology 
in the pathophysiology of AD (Clifford R Jack et al., 2013). DLMRI scores are found strongly 
linked to tau pathology in the entorhinal cortex, a region where AD pathology begins (Braak & 
Braak, 1991). The DLMRI scores’ superior performance likely reflects this sensitivity. It is 
possible, therefore, that tau-PET would outperform DLMRI score and other biomarkers. ADNI 
has only begun acquiring tau-PET in 2015, and there is currently insufficient data to test this 
prediction in our experimental design.  
 The fact that DLMRI scores outperformed biomarkers of amyloid and tau pathology in 
predicting time to dementia prediction is less surprising. As a biomarker of neurodegeneration, 
this finding agrees with prior studies (S.M. Landau et al., 2010; Vemuri et al., 2009) and with the 
current model for the temporal sequence of AD pathophysiology (Clifford R Jack et al., 2013). 
Since neurodegeneration occurs last, accurate biomarkers of it are most proximal to the 
development of dementia.  
 The strength of this study is also its potential weakness. Relying on progression to AD 
dementia as a way to retroactively identify patients with prodromal AD sidesteps the limitation 
that precise biomarker cutoffs for prodromal AD are not yet known. We designed the analysis 
based on prior studies, that suggest that the majority of MCI patients with prodromal AD will 
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progress within 4-5 years (Visser et al., 2006). Our analysis confirmed this assumption Figure A-4. 
Furthermore, approximately half of the MCI cohort ended up having prodromal AD, which agrees 
with previous approximations (Vos et al., 2015). Still, there are likely a minority patients in the 
stable MCI category who are harboring prodromal AD at baseline. The number of misclassified 
patients is likely to be low (Vos et al., 2015), and so this potential imprecision would not be 
expected to significantly alter our results. Tracking stable MCI patients for longer periods might 
address this concern, but would in fact raise a new one. Because of AD’s high incidence in older 
populations, when tracking patients for a decade or more, some are expected to develop AD de 
novo after the baseline evaluation. At the very least, we can conclude that the results are beyond 
reproach for a 5-year time window after initial evaluation, a clinically meaningful epoch for both 
patients and health care providers.  
 Validating that deep learning can enhance the clinical utility of MRI is the most important 
implication of this study, we consider this study a proof-of-principle for deep learning, and not 
necessary for our specific version of it.  
 The current standard of care when evaluating a patient with MCI suspected of having AD 
is to order “neuroimaging studies” (Albert et al., 2011), most typically the conventional MRIs from 
which the DLMRI scores are derived. The rationale for this recommendation and its routine 
clinical implementation is not to “rule in” AD, but rather to exclude other non-neurodegenerative 
causes of dementia, such as strokes, bleeds, and tumors. Deep learning algorithms that can extract 
useful information from MRI’s already acquired, for prodromal AD detection, have the additional 
advantage of reducing patient burden and cost incurred by lumbar punctures, injection of 




3.3 Age estimation in normal aging 
3.3.1 Introduction 
Age estimation is a way to study normal aging from a discriminative perspective, summarizing the 
age-related patterns of individuals and can also reveal the underpinnings that characterize the aging 
process. Besides normal aging, age factors into most diseases. Patterns that occur through the 
normal aging process must be accounted for when studying the diseases-specific patterns. The 
deviance of the estimated age from the chronological ages have shown utility in certain diseases, 
especially those thought to emulate advanced age state. 
 Brain age can be specifically defined as the estimated age using brain characteristics based 
on normal aging population. It can be regarded as fitting a complicated normal reference equation 
of age, deviance of which reflects abnormality. Brain age derived this way has been linked to 
education and self-reported physical activity (Steffener et al., 2016), and has been utilized in 
disease characterization including AD (Gaser et al., 2013), schizophrenia (Hugo G. Schnack et al., 
2016), traumatic brain injury (Cole, Leech, & Sharp, 2015), etc., where deviation from normal 
aging trajectory implicates disease state. 
 There are three factors embedded in the definition of brain age: 1) the brain characteristics, 
2) normal aging population, 3) estimation. 
 The brain characteristics can be derived from many sources, neuroimaging is the most 
common and comprehensive way to characterize the brain state in vivo. Within neuroimaging, 
there are studies using EEG (Electroencephalogram) (Al Zoubi et al., 2018), DTI (diffusion tensor 
imaging) (Mwangi, Hasan, & Soares, 2013), resting state BOLD fMRI (H. Li, Satterthwaite, & 
Fan, 2018), which focus on different aspects of brain states. 
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 But the most common modality in brain age estimation is T1w structure MRI which reveal 
anatomical characteristics of the brain. Neuroanatomical characteristics are sensitive and robust 
biomarkers for aging process (Walhovd et al., 2011). Practically, as one most widely available and 
standardized neuroimaging modality, T1w structural MRI can be easily acquired for a large 
population. And within structural MRI modality, studies have utilized derived summary variables 
such as regional volumes or thickness (Valizadeh, Hänggi, Mérillat, & Jäncke, 2017), and also raw 
MRI scans (Cole et al., 2017). 
 And secondly, a dataset that best represent the studying sample is crucial since the model 
reflects the knowledge distilled from the training population. In this study, we propose using a 
dataset aggregated from publicly available multi-center neuroimaging datasets, which represent a 
diverse healthy population. This healthy study population is both in a larger scale than any of the 
age estimation studies before and is also carefully designed to be best suited for age estimation 
task with even age distribution across adult life span. 
 Lastly, with adequate study population and brain characteristics, the age is estimated based 
on statistical machine learning frameworks. Another way to formulate this problem is to extract 
generalizable features from the brain that can best capture the chronological age of a person given 
that the person is experiencing typical aging process that is present in general healthy population. 
Numerous traditional machine learning methods have been proposed for age estimation including 
relevance vector machine (Ashburner, 2007; Franke, Ziegler, Klöppel, & Gaser, 2010), Gaussian 
process (Gutierrez Becker, Klein, & Wachinger, 2018; Lancaster, Lorenz, Leech, & Cole, 2018), 
random forest (Konukoglu, Glocker, Zikic, & Criminisi, 2013), hidden Markov model (B. Wang 
& Pham, 2011), non-negative matrix factorization (Varikuti et al., 2018), etc.. Deep learning based 
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methods are very suited for this task provided enough training data, and has been previously 
applied in (Cole et al., 2017) and demonstrated good performance.  
 Similar to the deep learning AD classification study, we also plan to explore the predictive 
regions in the regression task with ablation experiments and activation map based post hoc 
interpretation method. 
 In summary, we utilize a 3D deep convolutional neural network based regression model to 
estimate age using T1w structural MRI volumes from a diverse multi-study population that is 
sampled with even age distribution across adult age span. We demonstrate superior performance 
both in the hold-out test set from the same custom population and also in an independent life-span 
test set reported in previous studies. 
 
3.3.2 Methods 
We describe the population and the experimental setup used in this study. The MRI preprocessing 
steps, and the CNN (Figure 3-19) used to estimate age are very similar to the AD study, and are 
thus referring to sections 3.1.2.2 and 3.1.2.4. We also explored different variants of 3D ResNet 
models (He, Zhang, Ren, & Sun, 2015) ('resnet18', 'resnet34', 'resnet50', 'resnet101', 'resnet152') 
but did not show better performance. We then propose regionality analysis to interpret the model 




Figure 3-19. The convolution neural network architecture for age estimation. The only 
difference compared with Figure 3-2 is that the final convolutional output is flattened and fed into 
one fully-connected (FC) layer with linear output (red arrow). 
 
3.3.2.1 Study Population 
It is necessary to build an adequate neuroimaging dataset for age prediction in the full adult life 
span, especially given study recruitment criteria that are not necessarily evenly distributed. Recent 
progress in open imaging dataset greatly facilitates the possibility. In this work, we collect more 
than 30,000 T1w MRI scans from multiple open neuroimaging datasets. The list of the datasets 
used in this study with the full names and sources are listed in Table A-1. Among those, we only 
include subjects with clear indication of normal neurological evaluations. Basically, we exclude 
subjects with any neurological or psychiatric disease, and also subjects with no clear diagnosis 
label documented. We also chose 18 as the minimum age to cover the adulthood and also to avoid 




Figure 3-20. The age distribution of the age estimation study population. A) The age 
distribution of the raw dataset consisted of 10,158 scans; B) the age distribution of the dataset 
consisted of 6,142 unique subjects; C) the age distribution of the evenly sampled dataset. 
 This results in 10,158 MRI sessions, reflecting one of the largest and most heterogeneous 
structural brain MRI study ever conducted, the statistics are summarized in Table 3-4. However, 
as shown in Figure 3-20 (A), where we illustrate the raw age distribution, the age distribution of 
the population is highly unbalanced. Although there are studies covering the full age span 
including normal aging studies Cam-CAN (Taylor et al., 2017), IXI, SALD (Wei et al., 2018), 
DLBS (Rodrigue et al., 2012), OASIS-1 (Marcus et al., 2007), and consortium based studies such 
as CoRR (X.-N. Zuo et al., 2014), SchizConnect (L. Wang et al., 2016), many of the public imaging 
studies either focused on age-related disease in the elder population including ADNI, AIBL (Ellis 
et al., 2009), OASIS-2 (Marcus, Fotenos, Csernansky, Morris, & Buckner, 2010), PPMI (Marek 
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et al., 2011), NIFD; or focused on young subjects including BGSP (Holmes et al., 2015), SLIM 
(Liu et al., 2017). 
Table 3-4. Multi-center datasets used in deep learning and age estimation. 






ADNI  2423 438 56.3 - 95.8 76.64±6.05 1223/1192 217/221 
AIBL  781 457 60 - 92 72.86±6.53 359/421 199/258 
NIFD  428 136 36.9 - 85.2 65.76±7.66 185/243 59/77 
IXI  561 561 20.0 - 86.3 48.67±16.47  248/313 248/313 
BGSP  1566 1566 19 - 35 21.54±2.89  661/905 661/905 
Cam-CAN  652 652 18 - 88 54.30±18.59  322/330 322/330 
OASIS-1  316 316 18 - 94 45.09±23.90  119/197 119/197 
OASIS-2  145 56 60 - 97 76.54±7.99 52/93 19/37 
SALD  467 467 19 - 80 45.07±17.39  168/297 168/297 
SLIM  972 561 18 - 28.5 20.68±1.40  425/547 244/317 
PPMI  130 74 30.6 - 81 60.95±10.85  91/39 48/26 
SchizConnect  742 567 18 - 70 35.36±12.76  429/313 338/229 
DLBS  301 301 20.6 - 89.1 53.62±19.92 115/186 115/186 
CoRR  1326 642 18 - 83 28.78±12.39  689/637 343/299 
total  10158 6142 18 - 97 47.92±24.89 4764/5783 2780/3362 
 To alleviate the potential bias toward a certain age group, we need to balance the age 
distribution in the training population. In this study, we adopt both oversampling and 
undersampling. Specifically, we oversample age ranges with less subjects by including the 
longitudinal follow-up sessions from the same subjects, which could be regarded as a natural 
augmentation. For age ranges with more subjects, we only include one scan per subject to increase 
the variability of the sample, and if the number is still much larger, we further undersample 
stratified on study and gender. 
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 We divided the populations into age bins and use the bin with the minimum number of 
subjects as the basis number. The age bins used in this study are [18, 20), [20, 25), [25, 30), ... , 
[85, 90), [90, 100). One interesting observation is that the [35, 40), [40, 45) are the two age ranges 
with fewest number of subjects, so we regard these two bins as one, and allowing repeated scans 
from same subjects, and use the number of scans as the base level. The other age bins having 
multiple scans per subject are [85, 90) and [90, 100] because of the relative lower number in the 
two age bins. We undersample the subjects in other bins. The final dataset consists of 2856 MRI 
sessions from 2694 subjects covering age range 18-97, with the mean age 54.34 years old, standard 
deviation 21.16 years old. The age distribution of the evenly sampled adult age span dataset is 
shown in Figure 3-20 (C).  
 
3.3.2.2 Experimental setup 
We design training, validation and test sets of subjects for model training and evaluation. Since 
validation set is used to choose the optimal parameters of the model, we need to build a diverse 
validation set reflecting general MRI scan distribution and population distribution. Similarly, a test 
set representative of the same population as the training and validation sets is important for 
evaluation. Given the even age-distributed dataset we described in the section above, we perform 
stratified split based on study and gender within each age bin: 8/10 as training set, 1/10 as 
validation set, 1/10 as test set, ensuring non-overlapping subjects and similar distribution of age, 
study, gender in the training, validation and test sets. 
 We also evaluated our model by testing it on an independent test set. In this study, we use 
the Cam-CAN study as an independent test sample. Aiming to study normal aging process, Cam-
CAN provided very even age-distribution across adult life-span and has been previously used as 
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an independent testing sample in (Lancaster et al., 2018). We have to point out that, ideally, the 
trained model should be able to apply to all kinds of population. But the result on an independent 
sample which usually reflects a homogeneous population or acquisition setting, might be over- or 
under-optimistic. 
 We also perform a test-retest experiment using an independent dataset of three subjects 
scanned 40 times in 30 days (Maclaren, Han, Vos, Fischbein, & Bammer, 2014) to test the 
reproducibility of the model. 
 
3.3.2.3 Comparison with model trained on unbalanced dataset 
We also trained the model using all scans from unique subjects (N = 6,142, Figure 3-20 B). We 
apply the trained model on the independent Cam-CAN dataset and study the distribution of MAE 
over chronological age groups. 
 Besides, a simple way to potentially correct the imbalance without adjusting the sampling 
of the dataset is re-weighting the samples, specifically, we assign different weights to different 
sample, with the weights in proportional to the inverse of the frequency of specific age segments. 
 
3.3.2.4 Neuropsychological and morphometric associations 
To test the utility of the estimated age in studying cognitive functions across adult life-span, we 
evaluate the association between the summary scores of Benton face recognition test (BFRT) and 
the estimated age in Cam-CAN dataset. 
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 Specifically, we use the difference of the estimated age and chronological age to measure 
the deviance of individual brain age from their chronological age, and we refer to this value as 
agediff hereinafter. 
 The BFRT is a commonly used neuropsychological instrument that can be easily and 
reliably administered in adult patients to test baseline visual memory and perception. We adopted 
the SubScore-1, SubScore-2, TotalScore (SubScore-1 + SubScore-2) as dependent variables in 
individual linear regression models incorporating gender, chronological age, agediff, and the 
interaction of chronological age and agediff: 
 
 Additionally, we evaluate the association between agediff with cortical thickness generated 
using FreeSurfer (Bruce Fischl & Dale, 2000), by performing a partial correlation with gender and 
chronological age as covariates. FreeSurfer parcellates the cortex into 68 regions, and can be 
combined bilaterally into 34 regions. 
 
3.3.2.5 Age activation map 
Class activation mapping (Selvaraju et al., 2017; Zhou et al., 2016) reflects a commonly used 
method for interpreting the classification using CNNs and has been previously used in CNN based 
medical image analysis (Feng et al., 2017) to marry potential disease pathology with classification 
findings. In this work, we use the idea of a class activation map in a regression setting by 
highlighting the small-valued gradient in grad-CAM framework. We used functions in the keras-
99 
 
vis package11. We generate the average activation map within each age group to investigate the 
age-specific pattern of underlying substrates for age estimation. 
 
3.3.2.6 Slice based age estimation 
Besides the post hoc saliency map based activation map method, we also propose ablation analyses 
methods focusing on part of the input data. We apply serial 2D CNNs for age estimation with the 
input being three consecutive slices along each axis. The network architecture of the 2D CNN is 
the identical to the 3D CNN architecture described in the previous section with the 3D operations 
replaced with the corresponding 2D operations. We report the estimation performance on the 
different set of 2D slices as the indication of predictive importance. 
 
3.3.2.7 Lobe based age estimation 
Besides sliced based age estimation, we proposed using another more neuroanatomically-informed 
way to study the regionality through ablation experiments at the lobe level. The individual lobe 
masks were generated following the section 3.1.2.8 or our previous study (Feng, Yang, et al., 2018). 
The ages were estimated focusing on each lobe individually. 
 





3.3.3.1 Age prediction 
In the hold-out test set from the same population distribution as the training and validation set, our 
model achieves an MAE of 4.06 years and r = 0.970. For the independent Cam-CAN test set, the 
model proposed in (Lancaster et al., 2018) achieved MAE = 6.08 years and r = 0.929 when the 
Cam-CAN data were pre-processed with the optimal parameters selected from the independent 
training sample. We tested out our model in Cam-CAN data, processing the T1w MRI images 
using the proposed pipeline. The relationship between the estimated age and chronological age in 
Cam-CAN is shown in Figure 3-21, where r = 0.96, MAE = 4.21 years, which outperforms the 
result in (Lancaster et al., 2018). We also observe two obvious “outliers” among the 652 subjects 
tested, further investigation is needed to pinpoint whether they are due to methodological reasons 
or pathological reasons. The results demonstrate our proposed model achieve an accurate 
estimation in all age segments. 
 





We evaluate the reproducibility of the algorithm in test-retest scans. We show the statistics in Table 
3-5 and Figure 3-22. We observe that there is a difference in the estimated age and actual reported 
age. But the difference is consistent over the sessions with around 1 year old standard deviation, 
demonstrating good reproducibility of the proposed model. 
Table 3-5. Test-retest reproducibility experiment results. 
Subject Actual age Estimated age mean Estimated age std 
Subj-1 26 25.19 1.07 
Subj-2 31 33.02 1.14 
Subj-3 30 27.06 0.81 
 
 




3.3.3.3 Comparison with results using unbalanced dataset 
We compare the results using unbalanced dataset with the MAE performance in Cam-CAN dataset. 
Using the unbalanced dataset achieves comparable overall MAE (4.27 years) as the balanced data. 
Re-weighting the samples helps slightly improves the MAE (4.17 years) than the balanced dataset 
despite using many more scans. Additionally, we observe the MAE using the unbalanced dataset 
is not evenly distributed across life-span: MAE is lower in the young age with more abundant data, 
as shown in Figure 3-23 (B). 
 This could introduce potential bias in life-span studies. Using sample re-weighting (Figure 
3-23 (C)) alleviates the problem, and using balanced dataset generates even distribution across 
age-span (Figure 3-23 (A)). 
 
Figure 3-23. Distribution of MAE of age estimation across life-span. (A) Age estimated using 
the balanced dataset. Each step in the red line indicate the MAE in that age group, the black dashed 
line indicates the overall MAE. (B) Age estimated using the unbalanced dataset. (C) Age estimated 




3.3.3.4 Neuropsychological and neuromorphometric association 
The association of the cortical thickness measures with the agediff is illustrated in Figure 3-24. 
The thickness of cortical regions are significantly associated with the agediff. In addition, out of 
the 68 regions measured, 51 regions have a stronger correlation with the estimated age than the 
chronological age. This is expected as the age estimated through structural MRI image is in 
principle more coupled to structural phenotypes. 
 
Figure 3-24. The partial correlation coefficients of agediff and cortical thickness measures. 
The red dashed line indicates α under multiple comparison of N=34 regions. 
 The association of the BFRT scores with the difference in the estimated age and the 
chronological age, and its interaction with chronological age are summarized in Table 3-6. 
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Table 3-6. Association with Benton face recognition scores 
 
 
3.3.3.5 Age activation maps 
It is expected the anatomical patterns characterizing different age groups to be different throughout 
lifetime but are consistent within a local age range. Thus the age activation maps were generated 
and illustrated every 5 years, in the same way as preparing the dataset. The 3D iso-surfaces of the 
average age activation maps are shown in Figure 3-26. The average age activation maps overlaid 
on the MNI152 template are shown in Figure 3-25 (Left). To accommodate the anatomical 
differences in different age groups, average T1w images within each age group were generated, 
and the corresponding age activation maps were overlaid, as shown in Figure 3-25 (Right). In the 
20s, the predictive region localizes to orbital-frontal regions, which are the regions having most 
significant age-related volume decline across life-span as shown in Figure 2-17 in the previous 
aging chapter. With increasing age, the predictive regions still localize to the vicinity, but there is 
a trend moving superiorly in 30s - 60s. In 60s - 80s, the pattern stays at similar location but becomes 
more diffuse (revealed as smaller iso-surface). In the 80s, the overlapped areas are mostly anterior 
cingulate cortex and lateral ventricle. 
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Figure 3-25. The age activation maps at different age groups. The age activation maps overlaid 
on the (Left) MNI152 template, and (Right) average T1w image within each age group, both with 





Figure 3-26. The 3D iso-surfaces (0.8) of the age activation maps at different age groups. 
 
3.3.3.6 Slice based age estimation 
The age estimation performance using 2D MRI slabs sliced at different coordinate planes is shown 
in Figure 3-27. The slices with the best performance are also illustrated. The patterns are more 





Figure 3-27. MRI 2D slice based age estimation. (Top row) The mean absolute error (MAE) of 
the estimated age on the test set using 2D slices at different locations, the red lines indicate the 
location with lowest MAE. MAEs larger than 10 are cut to 10 for illustration purpose. (Bottom 
row) The illustration of slices at the red line in the top row from the MNI152 template and the 
corresponding segmentation (the colors follow the FreeSurfer color lookup table). 
 
3.3.3.7 Brain lobe based age estimation 
The age estimation performance of models trained on different lobes and cerebellum are shown in 
Table 3-7, the model trained on the frontal lobe achieves the best age estimation performance, but 




Table 3-7. Age estimation performance achieved using individual lobes and cerebellum. 
Lobe Frontal Temporal Parietal Occipital Cerebellum Whole-brain 
Age MAE 5.33 5.81 6.37 7.66 6.20 4.06 
 
3.3.4 Discussion 
In this study, a large heterogeneous dataset of structural neuroimaging across the adult lifespan 
was aggregated from multiple publicly available data sources, from which we curated a uniformly 
distributed dataset, which is able to achieve estimation not biased toward certain age group, while 
maintaining training efficiency comparing with training with all the data weighted according to 
the abundance. 
3.3.4.1 Regionality 
The regionality analysis in this study revealed patterns of neuroanatomical contributions of normal 
aging. All analyses provide evidence for the prominence of frontal regions in age estimation. 
Frontal regions have been shown to be selectively implicated in normal aging through both 
neuropsychological studies and neuroimaging studies (Chetelat et al., 2013; Gazzaley et al., 2005; 
Shamchi et al., 2017). In addition, the pattern shifts reflected in the class activation map based 
analysis imply the complexity of age-related structural changes. Neuropsychological evaluations 
targeting different cognitive domains and brain regions could help reveal the complexity in the 




3.3.4.2 Open questions 
One limitation comes from the definition of healthy subjects. The set of subjects might include 
subjects with pre-clinical AD or other disease at prodromal state that were not manifested in the 
clinical evaluation. However, this is not easily resolvable for cross-sectional studies. 
 Our analysis revealed the association between the divergence of estimated age from 
chronological age and BFRT performance. This suggests the potential utility of the estimated age 
at normal aging evaluation, in complement to other cognitive test and neuroimaging based 
measures. The utility relates to an open question of the aging process. It still requires further 
validation how the deviance would tell an individual's brain health status or even trigger clinical 
evaluations, since inter-subject differences in normal aging process definitely exist but are not well 
understood. And it is unclear whether this inherent variability increases with age or stays constant.  
 
3.3.4.3 Study sample composition 
Finally, while this study aims to study adult life-span, other studies aiming at different neurological 
conditions might benefit from other training dataset inclusion criteria, for example, autism and 
prodromal psychosis studies would definitely require the inclusion of subjects below 18, and 
subjects in middle and old age are less informative for the condition being explored. 
 
3.3.4.4 An overarching framework 
The Alzheimer’s disease diagnosis and age estimation studies constitute the key parts of a deep 
learning powered neurological condition evaluation workflow using T1w structural MRI. The 
workflow is designed with the inspiration from general neurological practice. In the deployment 
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scenario, given a new MRI from scanner, quality check and basic preprocessing will first be 
performed. And then the preprocessed image is fed into different models. At this stage, the deep 
learning inference can be done in less than a second for each model. With more data and more 
models, we can derive more variables. Taking together the wide availability of T1 weighted 
structural MRI, this pipeline has special practical advantage, and could be especially useful given 
limited resources. 
 One of the implications of supervised learning is that the desired properties of the model 
are largely determined by the input data and the associated labels. Thus, the workflow parallels 
the introduction of available datasets, and proposes potential future plans of data collection to 
complete the system. The specific algorithm also depends on the deployment scenario whether 
might it be inclusion/opt-in or exclusion/opt-out. 
 
Figure 3-28. A framework of workflow in neurological condition evaluations. 
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 The first step is to detect clear structural lesions such as brain tumor and stroke. This can 
be a supervised learning task using available datasets on brain tumor such as BRATS (Brain Tumor 
Segmentation) (Menze et al., 2015) from The Cancer Genome Atlas (TCGA) collection and stroke 
such as ATLAS (Anatomical Tracings of Lesions After Stroke) (Liew et al., 2018). These datasets 
also include manual segmentation of the lesions from experts. Thus, another way of utilizing these 
“dense” annotations is to train a stroke/brain tumor segmentation model. If no obvious (large 
cluster of) segmentation is predicted when applied on the new incoming data, the brain deems 
patent-lesion free. Another potential solution can be based on an unsupervised anomaly detection 
method, but is beyond the scope of current study. Patients with clear structural brain lesion would 
then be directed to clinical cares for further evaluation. 
 The next step is to test the existence of anatomical pattern of neurodegenerative disease. 
The ideal training dataset should consist of patients with different kinds of neurodegenerative 
disease versus healthy controls. If the anatomical pattern falls into neurodegenerative disease 
pattern, the next step is to further classify the specific disease including Alzheimer’s disease (AD), 
Parkinson’s disease (PD), Huntington’s disease (HD), frontotemporal dementia (FTD), Lewy 
Body Dementia (LBD), etc… And it has to be noted that some of the diseases can be further 
divided into subtypes, and certain diseases have overlapping pathological anatomical patterns, and 
might only be differentiated with the information from other data modality. 
 In section 3.1, I focused on Alzheimer’s disease diagnosis. Although not specifically 
designed to be specific to Alzheimer’s disease, the algorithm shows specificity in HD, PD, 
schizophrenia, and certain subtypes of FTD. In the future, it is possible to train a multi-class model 
with AD, control and other non-AD neurological disease. When a patient comes to the clinic and 
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presents MCI symptoms, the model can classify prodromal AD and evaluate time to conversion to 
AD. 
 If a subject is free of clear structural lesion and neurodegenerative pattern, then the subject 
lies in the spectrum of normal aging structurally. The location within the normal aging spectrum 
can be evaluated using the age estimation model. 
 The same set of system can be easily generalized to other MRI contrasts such as CBV, CBF 
or other imaging modalities such as PET, SPECT, CT. The model can always be used as a pattern 
extraction/recognition system with the probability simply interpreted as the similarity to a specific 
pattern (e.g. AD pattern). So it can always be used together with other sources of evidence such as 





4 Specific Aim 3: Enhancing the utility of CBV with retrospective 
CBV 
In this section, I introduced a technique enabling CBV generation retrospectively from clinical 
contrast-enhanced scans. The derivation of meaningful functional measures from such clinical 
scans is only possible through calibration to a reference, which was built from the largest collection 
of research CBV-fMRI scans from our lab. The method was validated in an epilepsy study and has 
demonstrated the potential to enhance the utility of CBV-fMRI by enriching the CBV-fMRI 
dataset. This technique is also applicable to AD and normal aging studies, and potentially enables 
deep learning based analytic approaches on CBV-fMRI with a similar pipeline used in structural 
MRI. 
4.1 Introduction 
Contrast-enhanced-MRI (CE-MRI) is a valuable and well-established diagnostic imaging tool used 
clinically to reveal signal changes reflective of oncological or inflammatory origin, as well as other 
underlying pathologies. CE-MRI is used annually in ~30 million procedures, and more than 300 
million procedures have been performed as of 2015 since 1988 (Lohrke et al., 2016). Many of the 
protocols for these scans overlap with the protocols of the requisite scans necessary for research 
CBV. 
 At its core, what distinguishes CBV-fMRI from other fMRI measures is the introduction 
of contrast agents, which provide higher spatial resolution and increase in intravascular signal to 
noise ratio (SNR) (Lin et al., 1999). Moreover, the majority of clinically ordered CE-MRI reflect 
intact vasculature (radiologically noted as “non-contrast enhancing”). As such, the signal changes 
114 
 
after contrast enhancement reflect the passive (venule and capillary) component of blood capacity, 
same as the research CBV-fMRI. 
 However, in a clinical setting, dynamic ranges of the signal in pre-contrast and post-
contrast acquisition may vary, especially if parameters related to the MRI voxel intensity values 
are left to scanner default parameters (as is common for MRI scanners unless otherwise specified), 
resulting in scaling problem. Whereas in research CBV-fMRI scans, the post-contrast and pre-
contrast image are in the same intensity translation and scaling system to accurately calculate the 
contrast uptake and determine voxel level CBV values. In certain experimental practices, an 
external intensity fiducial marker may be scanned at the same time to help with intermodal co-
registration (Woods, Mazziotta, & Cherry, 1993), where the intensity of the fiducial marker may 
be used to correct gross image intensity differences (Simor et al., 1995). But for most scan sessions, 
there are no external fiducial markers. In these scenarios, there is not a straightforward way to 
correct the image for potential quantitative CBV processing. But we can borrow the idea of 
external fiducial marker by finding an internal fiducial marker and validate the fiducial marker in 
a dataset with known dysfunction. 
 In this case study, I found an internal reference with the guidance from the largest collection 
of research CBV-fMRI, and explore this method on a unilateral temporal lobe epilepsy (TLE) 
lateralization task using MRI scans acquired for surgical evaluations. For TLE patients who are 
potential candidates for surgical treatment, lateralization of the epileptogenic zone is essential, and 
presents a challenge in the context of an unremarkable clinical structural MRI scan. Temporal lobe 
epilepsy laterality has been studied using many different imaging modalities including PET 
(Theodore, Sato, Kufta, Gaillard, & Kelley, 1997), ASL (Wolf et al., 2001), and DSC-MRI (Wu 
et al., 1999) for metabolism studies and structural MRI for structural studies (Mueller et al., 2009). 
115 
 
I interrogated the sub-regions of the hippocampus within this TLE group and potentially provide 
insight into the pathophysiology of the hippocampal circuit in epilepsy using an approach that can 




We included 304 pairs of correctly scaled pre-contrast scans and post-contrast scans in the study 
acquired from a collection of studies, which cover a broad population of subjects across different 
studies and age ranges, including follow-up scans of the same subjects. Both healthy subjects and 
subjects with various diseases, including schizophrenia, post-traumatic stress disorder, 
Alzheimer's disease, are included. The scans were acquired using CBV-fMRI sequence as 
described previously in normal aging study. Those reference scans are used to determine an 
appropriate reference region.  
 The research scan database is used to identify which class or region could be used as an 
internal reference region, as shown in the top. That finding is then applied to our clinical research 
scans shown in the bottom. For the research stream, brain extractions, regional and tissue 
segmentation are performed on the pre-contrast T1 weighted image. Post-contrast images are co-
registered to pre-contrast images and pre and post ratios are generated arithmetically on a voxel 
by voxel basis. For the clinical database, post-contrast scans are also co-registered in the same 
manner as the research database, in addition to brain extraction and tissue segmentation. White 
matter post/pre ratios, as further described in the text, were used to generate the scaling correction 
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factor (SCF). The SCF was then used to correct the post-contrast image which was used to generate 
the properly scaled CBV scans. 
 
Figure 4-1. The retrospective CBV pipeline. 
 For the retrospective clinical study, 34 unilateral TLE patients with pre-contrast and post-
contrast T1-weighted scans were screened from an internal database via retrospective chart review 
from 2011 to 2016. The laterality was determined based on video-scalp EEG recording of seizure 
onset with no evidence of seizures arising from the contralateral hemisphere. Other inclusion 
criteria include age>18 and IQ>70. Predicting a similar level of effect, the number of patients 
included exceeds an existing study demonstrating potential hypometabolism effect (Wolf et al., 
2001). Four patients were excluded from study due to space-occupying hippocampal lesions as 
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noted by a radiologist through clinical evaluation. Four additional patients were excluded due to 
MRI technical issues including significant mismatch of MRI acquisition parameters of pre and 
post-contrast scans (one case: pre-contrast image TE 3ms TR 16.67ms, post-contrast image TE 
5ms TR 19ms), severe artifact, prohibitive field of view or inadequate segmentation. The exclusion 
process was blind to patient diagnosis information. The receiver gain calibration was on all scans. 
Mesial temporal sclerosis (MTS) is not an exclusion criterion in this study, 5/26 patients have MTS. 
 
4.2.2 Scaling correction factor estimation with brain region segmentation 
A diagram demonstrating both the research and clinical databases and streams is shown in Figure 
4-1. The first step in attempting to identify a way to correct scaling within clinical scans is to align 
each of the clinical scan’s intensity. Borrowing the idea from external fiducial markers, we 
expected there might be an appropriate internal reference region relatively unaffected by contrast 
agent, which would be resilient to post-contrast signal change. In that case, the ratio of the intensity 
value of post-contrast image to pre-contrast image in the region of interest (ROI) would approach 
1.  
 The pre-contrast images are segmented using FreeSurfer (Bruce Fischl et al., 2002; Van 
Leemput et al., 2009) with the hippocampal subfield segmentation applied. All scans were quality 
checked by a trained reviewer. The post-contrast image was co-registered to the pre-contrast image 
through intra-subject linear co-registration using FSL FLIRT with six degrees of freedom and 
correlation ratio cost function (Jenkinson et al., 2002). Although both scans are of the same 
sequence parameters, we considered the presence of contrast enhancement to require a cost 
function befitting an inter-modal registration vs. intra-modal registration. The FreeSurfer 
segmentation masks were also resliced to the pre-contrast image space. The segmentation masks 
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were applied to the pre-contrast and co-registered post-contrast images. Mean values for post/pre-
contrast ratio values within ROIs were computed and used as features for subsequent processing. 
 Forty-five regions are segmented and labelled. To further refine the results, only regions 
with at least 100 voxels across scans are regarded robust and valid, which results in 38 regions. As 
shown in Figure 4-2, every region has increased signal with respect to the application of contrast 
agent.  
 Ideally, a region wholly unaffected by contrast uptake could be used to correct scaling. 
However, there is no consistent region within the brain with unequivocal preservation of signal. 
As such, we wish to find a region that can be consistently segmented with the lowest signal change 
e.g. coefficient of variation. WM would be expected to have the lowest based on its known cerebro-
vasculature. The coefficient of variation for cerebral WM (both left and right) post/pre-contrast 
ratio is the smallest of all the regions (Figure 4-2). 
4.2.3 Scaling correction factor estimation with tissue class segmentation 
Since white matter show consistency across scans, I explored the post/pre-contrast ratio on coarser 
tissue type segmentations. This provides advantages in computational time and robustness, which 
are very important for large-scale applications. 
 The pre-contrast image is first brain extracted using FSL BET (Smith, 2002). The brain 
extraction image is then segmented into WM, GM, and CSF using FSL FAST (Zhang, Brady, & 
Smith, 2001). To exclude the possible influence of GM on WM, the WM mask was eroded using 
a morphological 3-dimensional kernel. The post/pre-contrast ratio for each tissue type is generated 
the same way as described in the previous section. 
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 The ratios for all the scans in the training set are fitted to a normal distribution separately 
for each tissue type (or region). For a new test scan, the same processing steps are implemented, 
generating ratio for each tissue type. The ratios are substituted into the probability distribution 
functions fitted using the training set, generating normalized likelihood. Each ratio can be used to 
predict the scaling correction factor (SCF): 𝑆𝐶𝐹𝑅 = ?̂?𝑅/𝑟𝑅, where ?̂?𝑅 denotes the mean ratio value 
of the tissue R in the training set; 𝑟𝑅 denotes the ratio value for tissue R from the new scan. 
 
4.2.4 Retrospective TLE analysis 
The pre-contrast image was subtracted from the co-registered, scaling corrected post-contrast 
image to generate a raw subtracted image. The raw subtracted image was normalized by the mean 
value of grey matter to generate the relative CBV (rCBV) map. 
 I measured the rCBV in hippocampus and hippocampal subfields. The difference of 
contralateral and ipsilateral rCBV was used to study the epilepsy lateralization. In the individual 
analysis, raw data were first visualized with boxplots, and outliers were excluded outside of 1.5 
times the interquartile range (IQR). 
 
4.3 Results 
4.3.1 Screening internal reference region 
The results of screening using FreeSurfer segmentation are shown in Figure 4-2 and suggest that 
there is not an unaffected anatomically well-defined region with a ratio distributed around 1 in the 
FreeSurfer segmentation protocol. The scaling correction factor for each scan was estimated in 
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leave-one-out manner. The lowest mean squared error 0.00014, mean absolute error 0.00888 and 
standard deviation 0.01193 are achieved with left cerebral WM alone.  
 
Figure 4-2. Post/pre-contrast ratio values (mean ± std) for regions from FreeSurfer 
automatic subcortical segmentation pipeline. The regions are sorted in the order of the 
coefficient of variation (CV) of post/pre-contrast ratio. 
 For scaling correction using tissue segmentations. Using WM provides the best estimation 
regarding mean absolute error (0.00998), mean squared error (0.00017); whereas WM/CSF 
achieves slightly lower standard deviation (0.01292) and similar mean squared error (0.00017). 
The mean squared error, mean absolute error, and standard deviation levels are close to those 




4.3.2 Retrospective TLE analysis 
All clinical scans were within two standard deviation of the mean of the reference SNR distribution 
of our existing database. I found a statistically significant relative CBV decrease in the 
hippocampus ipsilateral to seizure-onset (paired t-test, NLeft-TLE = 17, NRight-TLE = 6, p < 0.05) with 
a mean contralateral ipsilateral difference 0.082 (standard deviation, 0.174). This finding is in line 
with previous studies suggesting ipsilateral hypometabolism in mesial temporal lobe using PET 
(Sarikaya, 2015; Theodore et al., 1997), ASL (Wolf et al., 2001) and DSC-MRI (Wu et al., 1999). 
 I found statistically significant mean rCBV change in the ipsilateral subiculum (paired t-
test, NLeft-TLE = 15, NRight-TLE = 6, p < 0.05) with a mean contralateral ipsilateral difference 0.177 
(standard deviation, 0.289). The results are trending when examining the left (p = 0.07) and right 
TLE (p = 0.11) patients respectively. I found no significant differences in hippocampal volumes 
or hippocampal subfield volumes (paired t-tests, p > 0.05) consistent with a recent large-scale 
study on brain region volumes in epilepsy without patent lesions (Whelan et al., 2016).  
 
Figure 4-3. The rCBV (left) and volume (right) of hippocampus contralateral and ipsilateral 
to the seizure onset. There is significant ipsilateral rCBV decrease but not significant structural 




Figure 4-4. The rCBV (left) and volume (right) of hippocampal subfields contralateral and 
ipsilateral to the seizure onset. There is statistically significant ipsilateral rCBV decrease in 
subiculum but no significant structural asymmetry for hippocampal subfields. The error-bars show 
the standard error of the mean. 
 
4.4 Discussion 
In the clinical contrast-enhanced MRI scans, I demonstrated that tissue segmentation based 
methods can achieve accurate scaling correction. WM plays the primary part in the estimation. 
The use of white matter as a reference region is also supported by results from brain volume 
measurement (Maclaren et al., 2014). However, in the event this method was to be used in a cohort 
with suspected WM signal changes like WM lesions or potential demyelinating diseases, this 
estimation model can incorporate other tissue classes to improve the robustness potentially 
mediated by non-uniform WM. 
Physiologically speaking, the white matter and cerebrospinal fluid should uptake little gadolinium; 
while grey matter being more densely vascularized should lead to increased contrast uptake. The 
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different uptake within the GM tissue class across regions across scans renders the ratio of GM 
more variant than WM. Partial volume effects may also contribute to this variance, though would 
likely affect the entire image uniformly. The segmentation of GM is likely to include regions of 
both micro and macro vasculature, which reflects the greatest contrast after contrast agent 
application. Though in principle, CSF uptakes little gadolinium; the segmentation of CSF is also 
prone to the influence of epicortical vasculature signal change or GM. The mean intensity ratio 
calculated using the eroded WM masks is similar to the value using the uneroded WM mask, which 
suggests a relative consistent distribution of gadolinium uptake across the periphery of the white 
matter and robust segmentation of white matter. 
 
4.4.1 Finer segmentation of white matter 
As white matter shows better homogeneity, I further explored the finer structure of cerebral white 
matter using the FreeSurfer parcellation results. For the WM voxels, the labels are assigned as the 
label of the closest GM voxel (Salat et al., 2009). As the number of labels is relatively large, the 
result is not shown here. The coefficients of variation are not significantly smaller than using WM 
as a whole. 
 
4.4.2 Epilepsy Lateralization 
Refractory TLE patients with structurally normal MRI scans often present a challenge to the 
surgical team with regard to lateralization of seizure onset. Our results suggest that CBV 
measurements may provide supportive information regarding the laterality of the epileptogenic 
region. Future studies may explore the role of CBV-fMRI. Additionally, our work suggests the 
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subiculum could be a driver of the metabolic dysfunction, supporting existing research on the 
subiculum’s role in epileptogenesis (Stafstrom, 2005). Electrophysiological studies on extracted 
hippocampal lesions in TLE have implicated the subiculum as the potential origin of interictal 
activity (Cohen, Navarro, Clemenceau, Baulac, & Miles, 2002).  
 
4.4.3 Limitations 
For inter-subject analysis, it is important to process all of the data in the same pipeline, as there is 
systematic bias using different methods (Klauschen, Goldman, Barra, Meyer‐Lindenberg, & 
Lundervold, 2009). The validity of the method depends on the stability of the within-method 
variation. Given the evaluation in publicly available software, FAST and FreeSurfer are likely to 
provide accurate and reproducible results for this analytical stream (Valverde, Oliver, Cabezas, 
Roura, & Lladó, 2015). With regards to FreeSurfer segmentations not revealing an unaffected 
region for contrast, it is possible that other structures (such as maxillary sinus) not defined in the 
segmentation template used in this study could be potentially accurate internal reference regions. 
 By using relative CBV, we are assuming the absence of global changes in CBV. Although 
hemispheric global grey matter CBV changes are unlikely, it will be important to examine those 
mean values more carefully to ensure that those do not inaccurately affect the results.  
 
4.4.4 Conclusions 
In this study, we provide evidence for ipsilateral hippocampal CBV changes in patients with 
unilateral TLE using intensity corrected steady state contrast enhanced CBV-fMRI. This was 
achieved with an analytical stream that was agnostic of scanner brand, type and protocol and can 
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be potentially implemented in an informatics system. Since these scans were acquired not for an 
imaging research study but for potential pre-surgical evaluation, this work demonstrates the 
potential of the proposed framework to characterize the functional profile of patients who may 
have retrospective contrast-enhanced scans. This analysis permits generating high-resolution 
metabolic maps using scans that would already be acquired for clinical evaluation. This applies 
not only to focal hippocampal metabolic dysfunction, but also to any indication where contrast 
enhanced MRI is standard or warranted. This analysis and methodological investigation serve as 
a case study of how novel analytical approaches may serve as a lens to refocus scan protocols to 
generate clinically relevant imaging measures. Additionally, future studies may focus on 
hippocampal sub-regional analysis and cognitive correlates, as certain sub-regions have been 
shown to exhibit selective vulnerability in different disease states. 
 
4.5 Future work 
Demonstrating its utility in a TLE lateralization task, the retrospective CBV technique opens up 
the possibility of standardizing CBV-fMRI from clinical scan database thanks to the large-scale 
research CBV collection. Future work includes collaboration with clinicians to expand the usage 
into other neurological conditions including Alzheimer’s disease and normal aging. 
 Another direction of enriching CBV-fMRI harvesting the current collection of CBV-fMRI 
scans and large-scale structural MRI scans is to learn a mapping between structural MRI and CBV-
fMRI. There are previous works working on synthesizing high-dose contrast-enhanced MRI scans 
from low-dose contrast-enhanced MRI scans (Gong, Pauly, Wintermark, & Zaharchuk, 2018) for 
tumor evaluation, but the practicality is still limited, and the utility for more subtle functional 
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changes was not demonstrated. Given the mapping, the structural MRIs can be first transformed 
to CBV-fMRI space and then first processed. This mapping could potentially improves the 
diagnosis despite deriving all information from structure because of the search space constraints 
set by this prior. 
 The enrichment of CBV-fMRI dataset potentially enables deep learning based analytic 






5 Discussion and conclusion 
In this thesis, I developed a study protocol of using large-scale neuroimaging data to study 
Alzheimer’s disease and normal aging from univariate parametric mapping based characterization 
to advanced machine learning based discrimination. Univariate parametric mapping can be best 
used for localization-based interpretation, which is important for understanding underlying 
neuroanatomical and neurophysiological by extracting mechanistic information. Whereas machine 
learning approach is best at discriminative analysis, which is important for accurate disease 
diagnosis. Both are important in terms of biomarker development. I further investigated 
localization through machine learning models, and the linkage of the machine learning derived 
measures with other biomarkers. Utilizing large-scale datasets, the developed protocol has the 
potential to advance the neuroscientific understanding and inform the clinical practice of 
Alzheimer’s disease and normal aging. 
 The protocol set up through this thesis work is able to transfer to other neurological disease, 
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AD: Alzheimer’s disease 
ADNC: Alzheimer's disease neuropathologic change score 
ADNI: Alzheimer’s Disease Neuroimaging Initiative 
AI: artificial intelligence 
AIC: Akaike information criterion 
ANOVA: Analysis of variance 
ANTS: Advanced normalization tools 
ApoE: Apolipoprotein E 
AUC: area under the curve 
AUROC: area under the receiver operating characteristic curve 
BFRT: Benton face recognition test 
BN: batch normalization 
BOLD: blood oxygen level dependent 
bvFTD: behavioral variant FTD 
CA: Cornu Ammonis areas 
CAM: class activation mapping  
CBS: Corticobasal syndrome 
CBF: cerebral blood flow 
CBV: cerebral blood volume 
CE-MRI: contrast-enhanced MRI 
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CERAD: Consortium to establish a registry for Alzheimer's disease score 
CN: cognitively normal 
CNNs: convolutional neural networks 
CNR: contrast-to-noise ratio 
CSF: cerebrospinal fluid 
CV: coefficient of variation 
DG: dentate gyrus 
DLMRI: deep learning derived MRI score 
DLPET: deep learning derived PET score 
DLAV45: deep learning derived AV45-PET score 
DLFDG: deep learning derived FDG-PET score 





FOV: field of view 
FTD: Frontotemporal dementia 
GRE: gradient echo 
HC: hippocampus 
HCP: Human Connectome Project 
HP: hippocampal formation 
ICV: intracranial volume 
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IFG: inferior frontal gyrus 
IQR: interquartile range 
LEC: lateral entorhinal cortex 
MAE: mean absolute error 
MCI: mild cognitive impairment 
MCIp: mild cognitive impairment progression  
MCIs: mild cognitive impairment stable 
MET: magnetoencephalography 
MLSUBCA: molecular layer of subiculum and CA fields 
MMSE: mini-mental state examination 
MPRAGE: magnetization prepared rapid acquisition gradient echo 
MRI: magnetic resonance imaging 
MTS: medial temporal sclerosis 
PD: Parkinson’s disease 
PET: positron emission tomography 
PIB: Pittsburgh Compound B 
PNFA: Progressive non-fluent aphasia, aka non-fluent/agrammatic variant primary progressive 
aphasia (nfvPPA) 
POI: parcellation of interest 
PRESUB: presubiculum 
PSP: Progressive supranuclear palsy 
RAVLT: Rey auditory verbal learning test 
ReLU: rectified linear unit 
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ROC: receiver operating characteristic 
ROI: region of interest 
RMSE: root mean squared error 
SCF: scaling correction factor 
SNR: Signal to Noise Ratio 
SPECT: Single-photon emission computed tomography 
svFTD: Semantic variant FTD, aka semantic variant primary progressive aphasia (svPPA) 
SUB: subiculum 
SUVR: Standardized uptake value ratio 
T1w: T1-weighted 
TEC: trans-entorhinal cortex 
TFE: Turbo Field Echo 
TLE: temporal lobe epilepsy 
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A.1 Supplementary figure and tables 
A.1.1 Specific aim 1 
 
Figure A-1. An illustration of hippocampal subregions. 
 
Figure A-2. An illustration of IFG subregions. 
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A.1.2 Specific aim 2 
 








Figure A-5. Correlation of DLMRI score with in vivo CSF biomarker measures. 
 




Figure A-7. Correlation of DLMRI score with morphometric measures. 
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A.2 Cross-sectional volumetric analyses in independent life-span normal aging 
studies 
Following the normal aging study covered in specific aim 2, we also performed cross-sectional 
volumetric analyses in three independent normal aging studies covering full adult age-span: Cam-
CAN (Taylor et al., 2017), IXI, DLBS (Rodrigue et al., 2012). The results show similar patterns 
with our cohort: dentate gyrus show most reliable age-related decrease within hippocampus, 
whereas the entorhinal show little age-related difference, IFG show age-related decrease but 
superior frontal region shows the most reliable age-related decrease. The demographic information 
of the three datasets are summarized in Table A-1 in section 3.3. 
 
Figure A-8. Age-related changes of left cortical volumes and the hippocampal subfield 




Figure A-9. Age-related changes of left cortical volumes and the hippocampal subfield 
volumes in DLBS dataset. 
 
Figure A-10. Age-related changes of the left cortical volumes and the hippocampal subfield 




A.3 AD classification specificity evaluation 
A.3.1 Introduction 
In real-world clinical evaluation, we might not be doing binary classification as the settings in the 
AD classification study. Besides the specificity concept in binary classification, there is a broader 
concept of specificity in the presence of other neurological conditions. In this section, we evaluate 
the specificity of the model directly applying the AD model on the data from patients who had 
other disease types.  
 In this section, I also present the structural profile of the diseases studied to explain the 
specificity. The structural profiles are generated in similar ways as the structural profile of AD. 
 
A.3.2 Methods 
The specificity was tested on as diverse disease population as possible, including frontotemporal 
lobe dementia and its different subtypes, Parkinson’s disease, and schizophrenia. Additionally, I 
analyze the structural profile of the different disease to understand the specificity together with 
what we learned from the interpretation result in AD classification. Specifically, the structural 
profile is the regional contrast with normal controls. 
 The FTD dataset is from frontotemporal lobar degeneration neuroimaging initiative and 
includes the subtypes of FTD: behavior-variant FTD (BV), semantic-variant FTD (SV), 
progressive nonfluent aphasia (PNFA), corticobasal syndrome (CBS), and progressive 
supranuclear palsy (PSP). The Parkinson’s disease dataset is from PPMI and includes Parkinson’s 
disease, and scans without evidence of dopaminergic deficit (SWEDD) patients. The schizophrenia 
dataset is from SchizConnect and includes patients with full-blown schizophrenia. Normal control 
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subjects are included in each dataset pertaining to each project’s inclusion criteria, and are used to 
generate the contrast patterns of the individual brain disorders. The basic demographical 
information is shown in Table A-2. 
Table A-2. The demographical information of the data used in the specificity study. 
FTD 
N = 365 
Control 
N = 165 
BV 
N = 61 
SV 
N = 29 
PNFA 
N = 35 
CBS 
N = 45 
PSP 
N = 60 
Age 63.3±7.2 61.6±6.6 63.2±6.6 68.6±7.5 66.7±6.8 71.0±7.6 
Gender M/F 58/77 40/21 16/13 16/19 21/24 28/32 
 
PD 
N = 275 
Control 
N = 65 
SWEDD 
N = 41 
PD 
N = 169 
Age 60.5±10.7 60.8±10.5 61.1±9.5 





The specificity results are shown in Figure A-11, as boxplots of the probabilistic outputs applying 
the AD model on the scans from other disease types. Semantic variant FTD show very tight 
distribution at high probability of being AD, while behavioral variant FTD and PNFA show large 
variance. The other syndromes generally show good specificity. 
Schiz 
N = 921 
Control 
N = 470 
Schizophrenia 
N = 451 
Age 34.6±12.4 35.8±12.5 




Figure A-11. The specificity of the AD prediction model in the presence of various brain 
disorders. 
 
A.3.3.2 Structural profile of other neurological diseases 
The structural profile of Parkinson’s disease is shown in Figure A-12. Patients with Parkinson’s 
disease show little brain atrophy, agreeing with a previous small-scale study (Worker et al., 2014). 
 The structural profile of FTD including subtypes (SV, BV, PNFA, PSP, CBS) is shown in 
Figure A-13. Semantic variant FTD is shown in Figure A-14. It’s noted that left entorhinal cortex, 
which overlaps with the region indicated by the class activation map from the AD classification 
model, is strongly implicated in SV. This explains the low specificity of our model in classifying 
SV. This structural pattern is consistent with previous studies showing primarily left lateralized 
atrophy of the anterior temporal lobe regions (Landin-Romero, Tan, Hodges, & Kumfor, 2016). 
 The structural profile of schizophrenia is shown in Figure A-15. Schizophrenia patients 
show moderate hippocampal atrophy. The patterns in general agree with previous works (T. van 
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Erp et al., 2015; T. G. M. van Erp et al., 2018). In addition, this group of schizophrenia patients 
are in a relative younger age than AD patients. 
 

















In brain disorders including dementia, the segmentation of atrophic brains is subject to large error. 
And it is the actual atrophic region that is the hallmark of the diseases. This is less of a problem 
for machine learning algorithms directly applied on the brain image. The parametric mappings 





A.4 CSF biomarker estimation from structural MRI 
A.4.1 Introduction 
In this chapter, I performed a preliminary analysis of estimating in vivo CSF biomarker levels from 
T1-weighted structural MRI, demonstrating a proof-of-concept for a data-driven approach of AD 
biomarker generation, mixing information from different categories and modalities. 
 
A.4.2 Methods 
I included 2954 MRI sessions from 1228 subjects, with valid Aβ and tau measures from CSF at 
the same visit as the MRI acquisition. The tau levels are log-transformed to alleviate the right-
tailed distribution. An illustration of the distribution is shown in Figure A-16. The convolutional 
neural network structure is the same as the one used in age estimation study. 
 





The root mean squared error (RMSE) of the Aβ estimation in the test set is 52.4, the correlation 
coefficient is 0.300 with a p-value 3.09E-7. The RMSE of the tau estimation in the test set is 50.4, 
the correlation coefficient is 0.416 with a p-value 3.88E-13. The scatterplots and linear fit are 
shown in Figure A-17. 
 
Figure A-17. The predicted CSF biomarker measures versus the ground truth. The red line 
indicates the linear fit. 
 
A.4.4 Discussion 
The current derived measures are still distance away from being used as a surrogate of CSF 
biomarkers, but they could be useful as correlates of CSF biomarkers, and at the same time reflect 
structural information as well. Although the correlation is significant showing the derived measure 
is reflective of the supervision signal, the actual estimated values still have large errors. One 
primary reason from the observation is the “regression toward the mean” phenomenon, which is a 
common problem in regression settings, and previously was described in age estimation studies 
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(Le et al., 2018). There could be potential ways to correct the trend e.g. assigning weights to each 
sample in proportion to the distance from mean in the training, and is a future direction of the study. 
 The Aβ estimation analysis showed relatively poor performance comparing with the tau 
analysis. While the potential methodology limitation cannot be ruled out, this might reflect the 
temporal sequence of the AD biomarkers as the structural MRI based biomarker is closer to tau 
biomarker than Aβ biomarker temporally. Or, this could reflect the relationship in the mechanism 
level: as previously revealed in a tau-PET study that pathological tau aggregation is closely linked 
to neurodegenerative patterns and clinical manifestations of AD (Ossenkoppele et al., 2016). But 




A.5 Diagnosis and regionality analysis of Alzheimer’s disease using PET 
A.5.1 Introduction 
In this study, I investigate diagnosing Alzheimer’s disease using PET with deep learning 
techniques, and perform corresponding regionality analysis. This study follows our previous study 
using deep learning on structural MRI for AD diagnosis and regionality analysis. Deep learning is 
known to be a general method incorporating feature engineering and classification in the same 
model, thus this work is also a proof of concept for the generalizability of the method. I have 
demonstrated in the previous study (Feng, Yang, et al., 2018), as also described in previous 
sections of thesis, that using deep learning technique on structural MRI can accurately diagnose 
Alzheimer’s disease from normal controls, and can predict MCI progression. Moreover, the 
predictive region identified through the deep learning technique overlaps with our prior knowledge 
about the pathophysiology of AD. The output probability (referred to as DLMRI score) can be 
used to summarize the structural information related to AD, and has shown potential clinical utility 
comparing with other measures. 
 Despite various practical advantages of structural MRI over other imaging modalities, 
structural MRI can only reflect regional atrophy by nature, while functional or other 
pathophysiological process might occur before atrophy. PET has long been explored for AD 
diagnosis. And there are several modalities of PET using different radioligands including FDG-
PET, AV45-PET, AV1451-PET, and so on. 
 In this study, I focus on using FDG and AV45 PET, which have been collected in a 
relatively large amount in ADNI. PET radioligand development is an active research area, and this 
study can be readily extended to other PET modalities in the future given abundant scans. In a 
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similar way to interpret the final output from the model on structural MRI, the output from the 
model on PET will be a data-driven summary score of the PET pattern related to AD. 
 FDG-PET is one of the most abundant PET modalities and has a long history of application 
in various areas of clinical research (de Leon et al., 2001; Herholz et al., 2002; Susan M. Landau 
et al., 2011). AV45-PET has demonstrated correlation with the presence and density of β-amyloid 
in the brain at autopsy (Clark et al., 2011).  
 2D deep learning has previously been applied on FDG-PET (Ding et al., 2018) and showed 




The PET data was acquired from ADNI (Jagust et al., 2015). ADNI-1 includes FDG-PET and PIB-
PET. ADNI-GO/ADNI-2 includes FDG-PET, AV45 (Florbetapir)-PET, and AV1451-PET in the 
late stage. ADNI-3 includes FDG-PET, AV45-PET, FBB (Florbetaben)-PET, and AV1451-PET. 
FDG-PET is the most abundant modality within ADNI. AV45-PET is the second most abundant 
modality. PIB-PET from ADNI-1 has just 228 scans from 103 subjects. As of 04/02/2019, FBB-
PET has 239 scans from 236 subjects, AV1451-PET has 824 scans from 672 subjects, and are still 
actively acquiring, but the majority scans are from cognitively normal and MCI subjects. 
 In this study, I focused on FDG-PET from ADNI-1 and ADNI-GO/ADNI-2, AV45-PET 
from ADNI-GO/ADNI2. For FDG-PET, I included 1445 scans (484 AD, 961 CN) from 682 
subjects (241 AD, 441 CN). For AV45-PET, I included 906 scans (180 AD, 726 CN) from 515 
subjects (151 AD, 364 CN). 
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 ADNI also provides prior-based composite scores of the PET measures derived from 
multiple ROIs. FDG composite score is the average FDG uptake of angular, temporal, and 
posterior cingulate (Susan M. Landau et al., 2011). AV45 composite score is the average AV45 
SUVR of frontal, anterior cingulate, precuneus, and parietal cortex relative to the cerebellum (S. 
Landau & Jagust, 2015). These composite methods are based on the priors of AD pathology and 
prior imaging studies, instead of the data-driven way used in machine learning. 
 
A.5.2.2 Analysis 
Since different PET modalities have different numbers of scans, I performed two major analyses. 
In the first analysis, I performed individual analysis for each individual modality. This can take 
advantage of the data availability most effectively. In the second analysis, I gathered common 
scans for all modalities. In the present study, the modalities are FDG and AV45. But in the future, 
when the overlap among different modalities increase, it is possible and straightforward to include 
more modalities. Within this major analysis, I proposed two sub-analyses: the first one performing 
classification using one modality at a time, and the performance of different modalities can be 
compared; the second sub-analysis involves stacking the different modalities, to maximize the 
discriminative power. Practically, this poses more restriction on the acquisition side, and 
additionally need to ensure registration on the processing side. In ADNI, the AV45 scans were 
already co-registered to the baseline FDG scans, so it was possible to directly stack the two 




A.5.2.3 Modality Merge 
In a deep learning model, the information from the two modalities can start to merge at different 
depth. The simplest method is to stack the two modalities at the input level, similar to the channels 
in an RGB image. However, despite the two modalities share the same spatial location, the inherent 
patterns in the individual modality could be different. Thus, I further explored the performance 
when merging the two modalities at different depth in the model. An illustration of the framework 
is shown in Figure A-18. 
 




Different from T1-weighted structural MRI, where the intensity of each individual pixel is a 
complicated reflection of the molecular composition of the underlying tissue and is not quantitative, 
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the value of each pixel in PET represents the level of specific binding targets. The normalization 
step, a standard preprocessing step in most image processing tasks, remains to be explored. Thus, 
in this study, I present results using both normalized and raw input images. 
 
A.5.2.5 DLPET scores 
Similar to the generation of DLMRI score, I can generate deep learning derived PET (DLPET) 
scores for analyses. I analyzed the DLFDG scores from FDG-PET and DLAV45 scores from 
AV45-PET in this study. 
 
A.5.2.6 MCI progression prediction 
I applied the model to the PET scans of baseline MCI subjects, and performed MCI progression 
prediction using ROC analysis and Cox proportional hazards regression survival analysis. The 
performance was compared with the PET composite measures and also DLMRI score derived from 
structural MRI. The table of demographical information is shown in Table A-3. The detailed 
analyses methods are similar and can be found in previous sections of DLMRI score analyses. 
Table A-3. Demographical and summary information of the MCI progression dataset with 
both PET scans and PET composite measures available. 
 MCI stable 
N = 154 
MCI progression 
N = 92 
Total 
N = 246 
age 70.9 ± 7.0 72.9 ± 6.6 71.7 ± 6.9 
sex M/F (%M) 88/66 (57.1) 51/41 (55.5) 139/107 (56.5) 
APOE ε4 frequency (2/1/0)  11/44/99 17/49/26 28/94/126 
Last visit FU year 4.43 ± 0.55 - - 
conversion year - 1.94 ± 1.16 - 
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DLMRI score 0.376 ± 0.163 0.632 ± 0.191 0.472 ± 0.214 
DLFDG score 0.109 ± 0.196 0.564 ± 0.362 0.279 ± 0.349 
DLAV45 score 0.174 ± 0.272 0.639 ± 0.328 0.348 ± 0.370 
FDG composite score 1.31 ± 0.11 1.16 ± 0.11 1.26 ± 0.13 
AV45 composite score 1.15 ± 0.19 1.41 ± 0.21 1.25 ± 0.23 
 
A.5.2.7 Association with the prior-based measures 
I further evaluated the association between the DLPET scores and the prior-based composite scores 
through correlational analysis. I used all available MCI baseline measures, with N = 660 for FDG-
PET, and N = 458 for AV45-PET. 
 
A.5.2.8 Class activation map 
The class activation maps were generated in a similar way as the one generated previously on 
structural MRI (Feng, Yang, et al., 2018). The average class activation map of AD cases was 
generated for interpretation. I also generated the average PET images of each PET modality to 
overlay with the class activation map to guide the localization in the class activation map. 
 
A.5.3 Results 
A.5.3.1 Individual modality classification performance 
The test AUROC values and accuracies using individual PET modalities including FDG and AV45 
are shown in Table A-4. 
Table A-4. The classification performance using individual PET modalities. 
 FDG AV45 
Normalized .932/88.0% .875/83.8% 
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Raw .910/92.0% .872/81.2% 
 
A.5.3.2 Classification performance using common scans of FDG and AV45 
The test AUROC values and accuracies using common FDG, AV45 scans, and stacking the FDG 
and AV45 at the input are shown in Table A-5. 
Table A-5. Classification performance using common scans of FDG and AV45. 
 FDG AV45 Stacking FDG, AV45 
Normalized .876/93.3% .896/90.0% .889/83.3% 
Raw .891/91.7% .893/86.7% .821/80.0% 
 
A.5.3.3 Classification performance merging FDG and AV45 features at different depth 
The test AUROC values and accuracies stacking the FDG and AV45 feature maps at different 
depth are shown in Table A-6. 
Table A-6. Classification performance stacking FDG and AV45 at different depth. 
Merge level 1 2 3 4 5 
Normalized .928/91.7% .872/91.7% .885/91.7% .882/90.0% .854/90.0% 
Raw .923/90.0% .901/91.7% .896/93.3% .892/91.7% .879/90.0% 
 
A.5.3.4 MCI progression prediction 
I derived DLPET scores from two models with highest accuracies indicated as bold in Table A-4 
and Table A-5. The ROC curves of MCI-progression and MCI-stable classification using 
composite PET scores, DLPET scores, and DLMRI score are show in Figure A-19, the AUROCs 
are shown in Table A-7. The Cox proportional hazards regression analyses statistics are shown in 
Table A-8. DLFDG scores show better time-to-conversion prediction performance. While DLFDG 
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and DLAV45 scores show better ROC performance than DLMRI score with no covariates, the 
performance is inferior after controlling for covariates. 
 
Figure A-19. ROC curves of different measures: (Left) Covariates age, gender, APOE ε4 
frequency; (Right) No covariate. 
Table A-7. AUROCs of the ROC analyses. 
 No covariate Controlling for covariates 
AV45 composite 0.820 0.752 
FDG composite 0.839 0.777 
DLAV45 score 0.859 0.783 
DLFDG score 0.877 0.789 
DLMRI score 0.845 0.810 
Table A-8. Cox proportional hazards regression survival analyses statistics. 
 






AV45 composite  3.50 0.485  7.22 5.37E-13 49.6 1.03 1.43 
FDG composite -8.79 0.979 -8.98 2.76E-19 84.3 1.18 1.34 
DLAV45 score  2.72 0.341  7.97 1.55E-15 68.7 0.017 0.742 
DLFDG score  2.92 0.299  9.76 1.71E-22 95.3 0.013 0.555 
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DLMRI score  4.94 0.560  8.82 1.15E-18 81.8 0.297 0.623 
 
A.5.3.5 Association with the prior-based composite scores 
I showed the prior-based composite scores strongly correlated with the DLPET scores, suggesting 
the association and also discrepancy between the prior-based and data-driven summary scores of 
PET scans. The scatterplots between the two measures are shown in Figure A-20. As the 
distribution of the data is dense in the range of 0 – 0.05, I also zoomed in on this range, and 
performed correlation in this range. The correlation statistics are shown in Table A-9. 
 
Figure A-20. Association between the deep learning derived PET summary scores and the 
prior-based composite scores. The red lines are the linear fits. 
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Table A-9. The correlation statistics between deep learning derived PET summary scores 
and the prior-based composite scores. 
 corr-coef p-value 
FDG -0.614 1.54E-69 
 DLFDG (0 - 0.05) -0.368 1.41E-10 
AV45  0.712 4.96E-72 
 DLAV45 (0 - 0.05)  0.230 1.10E-03 
 
A.5.3.6 Class activation maps 
The class activation map of the FDG-PET model is shown in Figure A-21. The predictive region 
localizes to medial occipitotemporal gyrus (lingual gyrus), inferior part of precuneus. The class 
activation map of the amyloid-PET model is shown in Figure A-22, one prominent region localizes 
to the right parietal regions, the other lesser prominent region localizes to left medial orbitofrontal 
region. 
 
Figure A-21. The AD class activation map of the FDG classification model overlaid on the 
average FDG map from the population. The class activation map localizes to medial 




Figure A-22. The AD class activation map of the AV45 classification model overlaid on the 
average AV45 map from the population. There are two prominent blobs in the class activation 
map, the more prominent one localizes to right parietal lobe (top), the lesser prominent blob 
localize to left medial orbitofrontal lobe (bottom). Note the range of the color-maps are different 
in the two sub-figures to best visualize the individual blob. 
 
A.5.4 Discussion 
Individually, FDG achieves good performance, AV45 achieves moderate performance, possibly 
because of more abundant training data for FDG-PET. Using the same set of data does show 
comparable performance between AV45 and FDG. Simply stacking two modalities as two 
channels of data did not lead to better classification performance than using individual modality 
alone. Intuitively, it increases the input dimensionality without change to the number of samples. 
Whereas, merging the feature maps of the two modalities after the first convolutional block but 
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not deeper layers improve the performance. One explanation could be that it is necessary to unify 
the latent representation of two modalities with some feature extraction operations before merging 
the information; however, it is beneficial to start the interaction between two modalities at lower 
representation. 
 The regions revealed through class activation map are consistent with previous studies and 
could potentially inform further neuroimaging studies. FDG hypometabolism in AD has been 
shown to localize to temporo-parietal regions (Hoffman et al., 2000). Amyloid accumulation 
revealed through AV45 Aβ has been shown to preferentially start in the precuneus, medial 
orbitofrontal, and posterior cingulate cortices (Palmqvist et al., 2017). 
 One limitation when interpreting the result is that the result is inevitably affected by 
structural information. This further complicates the attribution of the derived scores. However, on 
the other hand, this presents a natural way to merge different sources of information, which is 
important for biomarker or diagnostic tool development. 
 While the DLPET scores show better performance in ROC analysis without covariate than 
DLMRI score, the performance becomes inferior including covariates into the model. This could 
be potentially related to the sample composition. 
 One future work worth exploring is the explicit inclusion of interaction between two 
modalities into the model. Interaction is a term very commonly adopted in regression analysis, and 
can be explicitly included in the input. It could be potentially helpful for the classification if the 




 The other future work is to apply the model to other datasets, e.g. OASIS-3, which has both 
FDG and AV45 scans. But preprocessing standardization across studies requires further 
exploration. 
 
